<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">48675</article-id><article-id pub-id-type="doi">10.7554/eLife.48675</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Native adiponectin in serum binds to mammalian cells expressing T-cadherin, but not AdipoRs or calreticulin</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-142781"><name><surname>Kita</surname><given-names>Shunbun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8937-0053</contrib-id><email>shunkita@endmet.med.osaka-u.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-143843"><name><surname>Fukuda</surname><given-names>Shiro</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-143844"><name><surname>Maeda</surname><given-names>Norikazu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-143845"><name><surname>Shimomura</surname><given-names>Iichiro</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Metabolic Medicine, Graduate School of Medicine</institution><institution>Osaka University</institution><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Adipose Management, Graduate School of Medicine</institution><institution>Osaka University</institution><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Metabolism and Atherosclerosis, Graduate School of Medicine</institution><institution>Osaka University</institution><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Boudker</surname><given-names>Olga</given-names></name><role>Senior Editor</role><aff><institution>Weill Cornell Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>James</surname><given-names>David E</given-names></name><role>Reviewing Editor</role><aff><institution>The University of Sydney</institution><country>Australia</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>24</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e48675</elocation-id><history><date date-type="received" iso-8601-date="2019-05-22"><day>22</day><month>05</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-10-13"><day>13</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Kita et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Kita et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-48675-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.48675.001</object-id><p>Adiponectin is an adipocyte-derived atypically abundant circulating factor that protects various organs and tissues through its receptors, AdipoRs, calreticulin, and T-cadherin. To identify the major binding partner of circulating native adiponectin, we expressed these receptors on the surface of HEK293 cells. Adiponectin, either that in mouse or human serum, purified from serum, or produced by mammalian cells, bound to cells expressing T-cadherin, but not to those expressing AdipoR1 or calreticulin. The stable introduction of T-cadherin and AdipoR1 into CHO cells resulted in the cell surface localization of these receptors. Native adiponectin in serum bound to cells expressing T-cadherin, not to those expressing AdipoR1. The knockdown of T-cadherin, but not AdipoRs resulted in the significant attenuation of native adiponectin binding to C2C12 myotubes. Therefore, native adiponectin binding depended on the amount of T-cadherin expressed in HEK293 cells, CHO cells, and C2C12 myotubes. Collectively, our mammalian cell-based studies suggest that T-cadherin is the major binding partner of native adiponectin in serum.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>adiponectin</kwd><kwd>T-cadherin</kwd><kwd>calreticulin</kwd><kwd>binding</kwd><kwd>receptors</kwd><kwd>cell surface</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002241</institution-id><institution>Japan Science and Technology Agency</institution></institution-wrap></funding-source><award-id>#16K09802</award-id><principal-award-recipient><name><surname>Kita</surname><given-names>Shunbun</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002241</institution-id><institution>Japan Science and Technology Agency</institution></institution-wrap></funding-source><award-id>#16K09801</award-id><principal-award-recipient><name><surname>Maeda</surname><given-names>Norikazu</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002241</institution-id><institution>Japan Science and Technology Agency</institution></institution-wrap></funding-source><award-id>#15H04853</award-id><principal-award-recipient><name><surname>Shimomura</surname><given-names>Iichiro</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>CREST</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Shimomura</surname><given-names>Iichiro</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>The Uehara Memorial Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Shimomura</surname><given-names>Iichiro</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Binding study of native adiponectin existing in serum supported the importance of T-cadherin but not AdipoRs nor calreticulin.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Adiponectin is a circulating factor that is secreted from adipocytes (<xref ref-type="bibr" rid="bib10">Hu et al., 1996</xref>; <xref ref-type="bibr" rid="bib15">Maeda et al., 1996</xref>; <xref ref-type="bibr" rid="bib20">Nakano et al., 1996</xref>; <xref ref-type="bibr" rid="bib23">Scherer et al., 1995</xref>). Three types of receptors have been identified for this uniquely abundant circulating protein: AdipoRs, calreticulin, and T-cadherin.</p><p>AdipoR1 was discovered by expression cloning from a C2C12 myotube cDNA library through evaluations of the binding of biotin-labeled globular adiponectin produced in <italic>E. coli</italic> as bait (<xref ref-type="bibr" rid="bib31">Yamauchi et al., 2003</xref>). It belongs to the PAQR receptor family, which has a 7-transmembrane domain with an opposite topology to the GPCR family (<xref ref-type="bibr" rid="bib29">Tang et al., 2005</xref>).</p><p>Calreticulin is an endoplasmic reticulum (ER) luminal Ca2+-buffering chaperone that exists in the ER of cells (<xref ref-type="bibr" rid="bib17">Mendlov and Conconi, 2010</xref>; <xref ref-type="bibr" rid="bib18">Michalak et al., 2009</xref>). Cell surface exposure to calreticulin was initially reported to initiate the clearance of viable or apoptotic cells through binding to LRP on phagocytes (<xref ref-type="bibr" rid="bib9">Gardai et al., 2005</xref>). A subsequent study demonstrated that adiponectin opsonized apoptotic cells, and the phagocytosis of cell corpses was mediated by the binding of adiponectin expressed in insect cells or <italic>E. coli</italic> to calreticulin on the macrophage cell surface (<xref ref-type="bibr" rid="bib26">Takemura et al., 2007</xref>).</p><p>T-Cadherin was discovered by expression cloning from a C2C12 myotube cDNA library through evaluations of cell binding to coated recombinant adiponectin produced in HEK293 mammalian cells (<xref ref-type="bibr" rid="bib11">Hug et al., 2004</xref>). It is classified as a member of the classical cadherins, such as E-cadherin and N-cadherin, due to its high homology of five extracellular cadherin repeats (<xref ref-type="bibr" rid="bib12">Hulpiau and van Roy, 2009</xref>). However, T-cadherin is a unique cadherin with a glycosylphosphatidylinositol (GPI) anchor on its C terminus and does not possess the transmembrane or intracellular domain generally required for signaling, which may hinder the function of T-cadherin as an adiponectin receptor.</p><p>The adiponectin protein accumulates in tissues, such as the heart, muscle, and vascular endothelium, through binding with T-cadherin (<xref ref-type="bibr" rid="bib5">Denzel et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Fujishima et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Matsuda et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Parker-Duffen et al., 2013</xref>; <xref ref-type="bibr" rid="bib27">Tanaka et al., 2019</xref>). In T-cadherin null mice, the accumulation of the adiponectin protein was completely absent in these tissues, and, thus, HMW multimer adiponectin accumulated in blood (<xref ref-type="bibr" rid="bib5">Denzel et al., 2010</xref>; <xref ref-type="bibr" rid="bib16">Matsuda et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Parker-Duffen et al., 2013</xref>). These findings were in contrast to the lack of significant changes in plasma adiponectin levels in AdipoR1- and R2-double knockout mice (<xref ref-type="bibr" rid="bib32">Yamauchi et al., 2007</xref>). Human SNP studies including GWAS also indicated the importance of T-cadherin, but not AdipoRs or calreticulin, for plasma adiponectin levels, cardiovascular diseases, and glucose homeostasis (<xref ref-type="bibr" rid="bib1">Buniello et al., 2019</xref>; <xref ref-type="bibr" rid="bib2">Chung et al., 2011</xref>; <xref ref-type="bibr" rid="bib4">Dastani et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Kitamoto et al., 2016</xref>; <xref ref-type="bibr" rid="bib19">Morisaki et al., 2012</xref>).</p><p>Numerous studies have attributed the functions of adiponectin to either of these receptors by showing a decrease in their functions via the genetic loss or mRNA knockdown of their receptors, including AdipoRs (<xref ref-type="bibr" rid="bib24">Straub and Scherer, 2019</xref>; <xref ref-type="bibr" rid="bib33">Yamauchi et al., 2014</xref>; <xref ref-type="bibr" rid="bib31">Yamauchi et al., 2003</xref>; <xref ref-type="bibr" rid="bib32">Yamauchi et al., 2007</xref>), calreticulin (<xref ref-type="bibr" rid="bib26">Takemura et al., 2007</xref>), and T-cadherin (<xref ref-type="bibr" rid="bib5">Denzel et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Fujishima et al., 2017</xref>; <xref ref-type="bibr" rid="bib22">Parker-Duffen et al., 2013</xref>; <xref ref-type="bibr" rid="bib27">Tanaka et al., 2019</xref>). However, the direct binding of native adiponectin in biological fluids, such as serum, to its receptor warrants further study.</p><p>We herein demonstrated that native adiponectin in serum bound to cells expressing T-cadherin, but not to those expressing AdipoRs or calreticulin.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><p>We investigated the binding of native adiponectin in serum to three adiponectin receptors by transiently overexpressing the cDNA of each receptor in HEK293 cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We directly examined mouse serum as the ligand solution, including the most native adiponectin, purified adiponectin from mouse serum (<xref ref-type="bibr" rid="bib8">Fukuda et al., 2017</xref>), and full-length recombinant adiponectin produced in HEK293 cells. Native-PAGE showed differences in the distribution of molecular species between serum or purified adiponectin and recombinant adiponectin (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Recombinant adiponectin contained a lower amount of HMW multimer adiponectin than mouse serum and purified adiponectin from serum (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Transient transfection resulted in the successful overexpression of each receptor based on their expression levels quantified by RT-qPCR (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The treatment of cells with different preparations of adiponectin at 4°C for 1 hr resulted in the binding of prepared adiponectin only to cells expressing mouse T-cadherin (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Mouse serum and purified adiponectin showed similar binding, whereas recombinant adiponectin containing a lower amount of 6-mer and the HMW multimer exhibited markedly weaker binding (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). The results of a native-PAGE analysis showed that more than 6-mer of multimeric adiponectin specifically bound to cells expressing mouse T-cadherin (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), which is consistent with previous findings (<xref ref-type="bibr" rid="bib8">Fukuda et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Hug et al., 2004</xref>). The dose-response study revealed the specific and saturable binding of native adiponectin in serum to cells expressing T-cadherin (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.48675.002</object-id><label>Figure 1.</label><caption><title>Mouse serum adiponectin binds only to the hek293 cells expressing t-cadherin.</title><p>(<bold>A</bold>) Experimental outline. HEK293 cells were transfected with mammalian expression vectors coding mouse T-cadherin (<italic>mCdh13</italic>), Calreticulin (<italic>mCalr</italic>), or AdipoR1 (<italic>mAdipor1</italic>). (<bold>B</bold>) Native-page analysis of adiponectin preparations. Adiponectin concentrations were measured by ELISA and the equal amount (50 ng) of adiponectin was analyzed. (<bold>C</bold>) Absolute copy numbers of mRNA levels of mouse <italic>mCdh13</italic>, <italic>mCalr</italic>, <italic>mAdipor1</italic>, and <italic>mAdipor2</italic> were quantified. (<bold>D</bold>) Binding of adiponectin to HEK293 cells expressing none (N), mock (M), T-cadherin (T), or AdipoR1 (R1) (<bold>E</bold>) Dose-response cell-based binding study. Mouse serum (20 μg adiponectin/mL) was diluted and applied to the cells expressing mock or T-cadherin (left). The bound adiponectin was evaluated by blot intensity (right). Cell lysate following binding was separated by SDS-page and native-page. Essentially same results were obtained from more than three independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48675-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.48675.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Mouse serum adiponectin binding.</title><p>(<bold>A</bold>) Binding of mouse adiponectin in mouse serum to HEK293 cells. Multimer analysis of bound adiponectin by native page. Essentially same results were obtained from more than three independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48675-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.48675.004</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Human serum adiponectin binds only to the hek293 cells expressing t-cadherin.</title><p>(<bold>A</bold>) Experimental outline. HEK293 cells were transfected with mammalian expression vectors coding human T-cadherin (<italic>hCDH13</italic>), Calreticulin (<italic>hCALR</italic>), or AdipoR1 (<italic>hADIPOR1</italic>). (<bold>B</bold>) Absolute copy numbers of mRNA levels of human T-cadherin (<italic>hCDH13</italic>), Calreticulin (<italic>hCALR</italic>), AdipoR1 (<italic>hADIPOR1</italic>), and AdipoR2 (<italic>hADIPOR2</italic>) were quantified. (<bold>C</bold>) Binding of human adiponectin in human serum to HEK293 cells. (<bold>D</bold>) Multimer analysis of bound adiponectin by native page. Essentially same results were obtained from more than three independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48675-fig1-figsupp2-v2.tif"/></fig></fig-group><p>Similar results were obtained when human cDNAs were overexpressed and the binding of adiponectin in human serum was assessed (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A–D</xref>). We previously reported that purified recombinant T-cadherin bound purified adiponectin with an affinity of KD = 1.0 nM (<xref ref-type="bibr" rid="bib8">Fukuda et al., 2017</xref>). The present results showed the saturable binding of native adiponectin in serum to cells expressing T-cadherin, which is consistent with previous findings (<xref ref-type="bibr" rid="bib8">Fukuda et al., 2017</xref>). Regarding AdipoR1 and calreticulin, three possibilities have been proposed: they were not effectively translated, were not effectively presented on the cell surface, or did not support the binding of native adiponectin in serum to cells.</p><p>To confirm that all receptors were effectively translated and presented on the cell surface, we expressed affinity-tagged receptors in HEK293 cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We added a high-affinity PA tag (<xref ref-type="bibr" rid="bib6">Fujii et al., 2014</xref>) to the N termini of T-cadherin (<xref ref-type="bibr" rid="bib3">Ciatto et al., 2010</xref>) and calreticulin (<xref ref-type="bibr" rid="bib17">Mendlov and Conconi, 2010</xref>) and to the C terminus of AdipoR1 (<xref ref-type="bibr" rid="bib33">Yamauchi et al., 2014</xref>) such that each receptor exposed the PA tag outside of the cell. Transiently expressing cells were surface-biotinylated, and lysates were applied to streptavidin beads. Total cell lysates (<xref ref-type="fig" rid="fig2">Figure 2B</xref> Total) and streptavidin-captured cell-surface proteins (<xref ref-type="fig" rid="fig2">Figure 2B</xref> Cell surface) were analyzed by Western blotting. The anti-PA-tag antibody NZ-1 detected similar levels of all receptors in total cell lysates and cell surface fractions, indicating that these receptors were successfully translated and expressed on the cell surface. Although AdipoR1 poorly migrated on the SDS-PAGE gel, this may have been due to heat-induced protein crosslinking or aggregate formation during sample processing (<xref ref-type="bibr" rid="bib28">Tanford and Reynolds, 1976</xref>). The correct sorting of this protein to the cell surface suggested that AdipoR1 was expressed with the correct conformation on the cell surface. Under these conditions, a binding study with mouse serum revealed the dose-dependent binding of native adiponectin to cells expressing PA-tagged T-cadherin, but not to those expressing PA-tagged calreticulin or AdipoR1 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Taken together with the results of the overexpression study (<xref ref-type="fig" rid="fig1">Figure 1</xref>), native adiponectin in serum bound to cells expressing T-cadherin, but not those expressing calreticulin or AdipoR1.</p><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.48675.005</object-id><label>Figure 2.</label><caption><title>Cell surface expression of adiponectin receptors.</title><p>(<bold>A</bold>) Experimental outline of transient expression in HEK293 cells. (<bold>B</bold>) Surface protein biotinylation analysis. Cell surface biotinylated proteins trapped on Streptavidin beads were eluted and analyzed in SDS-page in two lanes; x1 and x5 concentrations. Note that PA-tag antibody NZ-1 react with human podoplanin (40 KDa) in addition to PA-tagged proteins. GAPDH; control cytosolic protein. (<bold>C</bold>) Binding of mouse adiponectin in mouse serum (MS) to HEK293 cells. (<bold>D</bold>) Experimental outline of stable CHO cells expressing adiponectin receptors. (<bold>E</bold>) stable expressions detected by NZ-1. (<bold>F</bold>) Binding of mouse adiponectin in mouse serum to CHO cells. Adiponectin-binding from western blots (left) was calculated and expressed in right graph. Data are mean ± SEM. n = 4 ***p&lt;0.01 (unpaired t-test). (<bold>G</bold>) Binding of NZ-1 antibody to CHO cells. NZ-1-binding from western blots (left) was calculated and expressed in right graph. Data are mean ± SEM. n = 4 ***p&lt;0.001 (unpaired t-test). (<bold>H</bold>) Confocal immunofluorescence micrographs of CHO cells stained with anti-PA tag antibody NZ-1 (green). Cell nuclei were counterstained with DAPI (blue). Scale bars = 250 nm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48675-fig2-v2.tif"/></fig><p>We then generated stably expressing CHO cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The successful expression of the receptors in these cells was confirmed by Western blotting (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Serum adiponectin binding was only observed on cells expressing PA-tagged T-cadherin (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). In contrast, the binding of the PA tag antibody NZ-1 to intact cells was detected on cells expressing PA-tagged T-cadherin and AdipoR1 (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). These results demonstrated that AdipoR1 was stably expressed on the cell surface with the expected topology of the PA tag outside of cells, but did not induce the binding of native adiponectin in serum. Calreticulin was not recognized by NZ-1 in the binding study (<xref ref-type="fig" rid="fig2">Figure 2G</xref>), suggesting that the PA tag at the N terminus of calreticulin was not accessible by NZ-1.</p><p>This may have been due to some steric hindrance because calreticulin with the N-terminal PA tag was detected on Western blots (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) and immunostaining of fixed and permeabilized cells by NZ-1 (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). Calreticulin is essentially an ER-resident protein (<xref ref-type="bibr" rid="bib9">Gardai et al., 2005</xref>; <xref ref-type="bibr" rid="bib26">Takemura et al., 2007</xref>). Therefore, stably expressed calreticulin in CHO cells may not have been sorted to the cell surface.</p><p>Based on these different approaches, we concluded that the expression of AdipoR1 may not promote native adiponectin binding. We also concluded that if calreticulin is expressed on the cell surface, it may not promote native adiponectin binding. The present results demonstrated that only the expression of T-cadherin on the cell surface may increase the binding of native adiponectin.</p><p>Since the above studies employed artificial expression systems, and AdipoR1 and T-cadherin were both identified from the C2C12 cDNA library (<xref ref-type="bibr" rid="bib11">Hug et al., 2004</xref>; <xref ref-type="bibr" rid="bib31">Yamauchi et al., 2003</xref>), we examined native adiponectin binding to C2C12 myotubes (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The absolute expression level of T-cadherin mRNA in differentiated C2C12 myotubes was markedly higher than that of AdipoRs (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We investigated the knockdown effects of these receptors on the binding of serum-containing adiponectin in C2C12 myotubes (<xref ref-type="fig" rid="fig3">Figure 3C,D</xref>). The introduction of RNAi before differentiation resulted in the effective knockdown of T-cadherin, AdipoR1, or AdipoR1 and R2 after 3 days of differentiation (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). The knockdown of T-cadherin resulted in significant reductions in adiponectin binding (<xref ref-type="fig" rid="fig3">Figure 3D,E</xref>). The knockdown of AdipoR1 or both AdipoR1 and R2 did not significantly reduce adiponectin binding (<xref ref-type="fig" rid="fig3">Figure 3D,E</xref>). Although slight decreases were observed in adiponectin binding by the knockdown of AdipoR1 or both AdipoR1 and R2, the strong correlation (R<sup>2</sup> = 0.9896) between T-cadherin expression and adiponectin binding at all experimental points suggested that these changes were due to the decreased expression of T-cadherin (<xref ref-type="fig" rid="fig3">Figure 3F,G</xref>). Collectively, these results indicated that native adiponectin binding also depends on the amount of T-cadherin expressed in C2C12 myotubes.</p><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.48675.006</object-id><label>Figure 3.</label><caption><title>Knockdown of T-cadherin but not Adipors nor calreticulin affected native adiponectin binding to c2c12 myotubes.</title><p>(<bold>A</bold>) Experimental outline. (<bold>B</bold>) Absolute expression levels of T-cadherin (<italic>mCdh13</italic>), AdipoR1 (<italic>mAdipor1</italic>), and AdipoR2 (<italic>mAdipor2</italic>) in differentiated C2C12 myotubes. (<bold>C</bold>) Knockdown efficiencies of adiponectin receptors. Data are mean ± SEM. n = 3 ***p&lt;0.001 (unpaired t-test). (<bold>D</bold>) Binding of native adiponectin in mouse serum to C2C12 cells. Bound adiponectin was shown in representative western blot with a-tubulin as internal control and T-cadherin. (<bold>E</bold>) Adiponectin-binding. Data are mean ± SEM. n = 4 ***p&lt;0.001 (unpaired t-test). (<bold>F</bold>) Amount of T-cadherin protein expression. Data are mean ± SEM. n = 4 ***p&lt;0.001 (unpaired t-test). (<bold>G</bold>) Correlation between bound adiponectin and T-cadherin protein expression. n = 16 a linear regression r2 = 0.9896.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48675-fig3-v2.tif"/></fig><p>Here, we simultaneously compared three adiponectin receptors. The expression of T-cadherin gave adiponectin binding, which is consistent with our previous finding showing that recombinant T-cadherin binds HMW adiponectin in a 1: one ratio with high affinity (<xref ref-type="bibr" rid="bib8">Fukuda et al., 2017</xref>). There was no detectable binding of adiponectin on the AdipoR or calreticulin. AdipoR was discovered by expression cloning. The overexpression of AdipoR was expected to promote ligand binding. The initial discovery of AdipoRs also indicated that HEK293 cells overexpressing AdipoRs bound <italic>E. coli</italic> recombinant globular adiponectin (<xref ref-type="bibr" rid="bib31">Yamauchi et al., 2003</xref>). Therefore, difficulties are associated with speculating about the much weaker affinity or the requirement for some ‘accessory’ proteins to confer adiponectin binding activity to AdipoRs.</p><p>Since numerous studies indicated that AdipoRs mediate adiponectin signaling in a number of cell types, an additional activating mechanism for AdipoRs by adiponectin, that is, the reductive or proteolytic generation of the trimer, monomer, and/or globular adiponectin, may exist. The results of the present study, which focused on the direct binding of native HMW adiponectin, may indicate the activation of AdipoRs by low-molecular-weight (LMW) forms. On the other hand, in the case of calreticulin, this was evidenced by a neutralizing antibody treatment inhibiting the adiponectin interaction with cells (<xref ref-type="bibr" rid="bib26">Takemura et al., 2007</xref>). Therefore, some ‘accessory’ proteins may be required to confer adiponectin binding activity to calreticulin.</p><p>T-cadherin binds clinically important HMW multimer adiponectin with high affinity (<xref ref-type="bibr" rid="bib8">Fukuda et al., 2017</xref>) and mediates adiponectin-induced exosome biogenesis and ceramide efflux to exosomes (<xref ref-type="bibr" rid="bib21">Obata et al., 2018</xref>). Such exosome-effect required T-cadherin, but not AdipoRs. The exosome mediates cell-cell communication by transferring signaling components such as microRNAs, bioactive lipids, and proteins in addition to its role in waste disposal (<xref ref-type="bibr" rid="bib13">Kita et al., 2019</xref>; <xref ref-type="bibr" rid="bib30">van Niel et al., 2018</xref>). The stimulation of exosome biogenesis by adiponectin was the first demonstration of a secreted factor modulating exosome biogenesis and secretion (<xref ref-type="bibr" rid="bib21">Obata et al., 2018</xref>). Adiponectin in serum or purified native adiponectin together with T-cadherin accumulated inside multivesicular bodies, the site of exosome generation, both in cultured endothelial cells and the in vivo wild-type mouse aorta (<xref ref-type="bibr" rid="bib21">Obata et al., 2018</xref>). The systemic level of exosomes in blood was decreased by approximately 50% following the genetic loss of adiponectin or T-cadherin, but was increased by the overexpression of adiponectin in mice (<xref ref-type="bibr" rid="bib21">Obata et al., 2018</xref>). The molecular mechanisms by which adiponectin stimulates exosome biogenesis are currently under investigation. We speculate that native HMW adiponectin with its multimeric structure may cause the higher-order clustering of T-cadherin, a membrane-anchored protein that resides in lipid rafts, and, thus, may stimulate exosome biogenesis. Adiponectin-induced increases in exosome biogenesis were not restricted to cultured endothelial cells because they were also observed in C2C12-differentiated myotubes (<xref ref-type="bibr" rid="bib27">Tanaka et al., 2019</xref>) These findings support T-cadherin mediating adiponectin functions as a receptor for native HMW multimer adiponectin (<xref ref-type="bibr" rid="bib13">Kita et al., 2019</xref>). The present results may further contribute to clarifying the activating mechanism of AdipoRs by LMW adiponectin, generated by reduction or proteolytic cleavage, followed by HMW adiponectin binding to cell surface T-cadherin.</p></sec><sec id="s3" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or <break/>resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Antibody</td><td valign="top">anti-mouse adiponectin</td><td valign="top">R and D</td><td valign="top">AF1119</td><td valign="top">goat polyclonal <break/>WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-human adiponectin</td><td valign="top">R and D</td><td valign="top">AF1065</td><td valign="top">goat polyclonal <break/>WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-T-cadherin</td><td valign="top">R and D</td><td valign="top">AF3264</td><td valign="top">goat polyclonal <break/>WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-α-tubulin</td><td valign="top">Cell Signaling</td><td valign="top">11H10</td><td valign="top">rabbit polyclonal <break/>WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-PA-tag (NZ-1)</td><td valign="top">FUJIFILM</td><td valign="top">012–25863</td><td valign="top">rat monoclonal <break/>WB (1:1000)</td></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">Cell Surface Biotinylation Kit</td><td valign="top">Thermo Fisher (Pierce)</td><td valign="top">89881</td><td valign="top"/></tr><tr><td valign="top">Biological sample (<italic>Mus musculus</italic>)</td><td valign="top">Serum</td><td valign="top">CLEA Japan</td><td valign="top">C57BL6J jcl</td><td valign="top">Freshly isolated from C57BL6J mice, male</td></tr><tr><td valign="top">Biological sample (<italic>Homo sapiens</italic>)</td><td valign="top">Serum</td><td valign="top"/><td valign="top"/><td valign="top">Freshly isolated from healthy volunteers, male</td></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Full-length mammalian recombinant mouse adiponectin</td><td valign="top">BioVendor</td><td valign="top">RD272023100</td><td valign="top"/></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">high-molecular weight purified mouse adiponectin</td><td valign="top"><xref ref-type="bibr" rid="bib8">Fukuda et al., 2017</xref></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>mRplp0</italic>_Fw</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">GGCCAATAAGGTGCCAGCT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>mRplp0</italic>_Rv</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">TGATCAGCCCGAAGGAGAAG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Adipor1</italic>_Fw</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">AATGGGGCTCCTTCTGGTAAC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Adipor1</italic>_Rv</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">GGATGACTCTCCAACGTCCCT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Adipor2</italic>_Fw</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">GGAGTGTTCGTGGGCTTAGG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Adipor2</italic>_Rv</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">GCAGCTCCGGTGATATAGAGG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>mCdh13</italic>_Fw</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">GCCCTCGTGAGCCTTCTTC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>mCdh13</italic>_Rv</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">CACCCTGAGGTCCGTGATGT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>mCalr</italic>_Fw</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">AAGATGCCCGATTTTACGCAC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>mCalr</italic>_Rv</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">CCCACAGTCGATATTCTGCTC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>hRPLP0</italic>_Fw</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">GGCGACCTGGAAGTCCAACT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>hRPLP0</italic>_Rv</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">CCATCAGCACCACAGCCTTC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>hCDH13</italic>_F</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">AGTGTTCCATATCAATCAGCCAG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>hCDH13</italic>_R</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">CGAGACCTCATAGCGTAGCTT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>hADIPOR1</italic>_F</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">TCCTGCCAGTAACAGGGAAG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>hADIPOR1</italic>_R</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">GGTTGGCGATTACCCGTTTG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>hADIPOR2</italic>_F</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">CTGGATGGTACACGAAGAGGT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>hADIPOR2</italic>_R</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">TGGGCTTGTAAGAGAGGGGAC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>hCALR</italic>_Fw</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">CTCTGTCGGCCAGTTTCGAG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>hCALR</italic>_Rv</td><td valign="top">Gene Design</td><td valign="top"/><td valign="top">TGTATTCTGAGTCTCCGTGCAT</td></tr><tr><td>Cell line <break/>(<italic>Homo sapiens</italic>)</td><td>HEK293 cells</td><td>ATCC</td><td>CRL-1573 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0045">CVCL_0045</ext-link></td><td>DMEM+10%FBS</td></tr><tr><td>Cell line <break/>(<italic>Cricetulus griseus</italic>)</td><td>CHO cells</td><td>ATCC</td><td>CCL-61 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0214">CVCL_0214</ext-link></td><td>Ham's F12+10%FBS</td></tr><tr><td>Cell line <break/>(<italic>Homo sapiens</italic>)</td><td>Plat-E cells</td><td>Cosmobio</td><td>RV-101 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_B488">CVCL_B488</ext-link></td><td>Ecotropic retrovirus packaging <break/>DMEM+10%FBS</td></tr><tr><td>Cell line <break/>(<italic>Mus musculus</italic>)</td><td>C2C12 cells</td><td>RIKEN cell bank</td><td>RCB0987 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0188">CVCL_0188</ext-link></td><td>C2C12 sleletal myoblast <break/>DMEM+10%FBS</td></tr><tr><td>Recomninant DNA reagent</td><td><italic>mCdh13</italic></td><td>This paper</td><td/><td>Materials and methods: plasmids</td></tr><tr><td>Recomninant DNA reagent</td><td><italic>mCalr</italic></td><td>This paper</td><td/><td>Materials and methods: plasmids</td></tr><tr><td>Recomninant DNA reagent</td><td><italic>mAdipor1</italic></td><td>This paper</td><td/><td>Materials and methods: plasmids</td></tr><tr><td>Recomninant DNA reagent</td><td><italic>hCDH13</italic></td><td>This paper</td><td/><td>Materials and methods: plasmids</td></tr><tr><td>Recomninant DNA reagent</td><td><italic>hCALR</italic></td><td>This paper</td><td/><td>Materials and methods: plasmids</td></tr><tr><td>Recomninant DNA reagent</td><td><italic>hADIPOR1</italic></td><td>This paper</td><td/><td>Materials and methods: plasmids</td></tr><tr><td>Recomninant DNA reagent</td><td><italic>mCat1</italic></td><td>This paper</td><td/><td>Materials and methods: plasmids</td></tr></tbody></table></table-wrap><sec id="s3-1"><title>Plasmids</title><p>General PCR techniques were used for the construction of plasmids. All primers were purchased from GeneDesign, Inc. The full-length cDNAs of human and mouse T-cadherin (<italic>mCdh13</italic>), AdipoR1 (<italic>mAdipor1</italic>), and calreticulin (<italic>mCalr</italic>) were cloned into pcDNA mammalian expression plasmid vectors. The PA tag sequence (GVAMPGAEDDVV) was attached to the N termini of mouse T-cadherin and calreticulin and the C terminus of AdipoR1. Mouse <italic>mCat1</italic> cDNA was cloned into a pcDNA mammalian expression plasmid vector.</p></sec><sec id="s3-2"><title>Cell lines</title><p>Mammalian cell lines were obtained from the American Type Culture Collection or RIKEN BRC CELL BANK. All cell lines negative for mycoplasma contamination were maintained under conditions indicated in Key resources table.</p></sec><sec id="s3-3"><title>Stably expressing CHO cells</title><p>PA-tagged receptor cDNAs were subcloned into the retrovirus packaging vector pMXs-neo, and the resultant vectors were used to transfect Plat-E cells, thereby generating recombinant retroviruses. CHO cells were transfected with a mouse <italic>mCat</italic> plasmid, and after 48 hr, the resultant cells were infected with recombinant retroviruses. G418 at 800 μg/mL was used to select stably introduced cells.</p></sec><sec id="s3-4"><title>Antibodies</title><p>The following primary antibodies were used: goat polyclonal anti-mouse adiponectin (AF1119, R and D), goat polyclonal anti-human adiponectin (AF1065, R and D), goat polyclonal anti-T-cadherin (AF3264, R and D), rabbit monoclonal anti-α-tubulin (11H10, Cell Signaling), rat monoclonal anti-PA-tag (human podoplanin PLAG sequence) (012–25863, FUJIFILM), and rabbit monoclonal anti-GPADH (14C10, Cell Signaling Technology).</p></sec><sec id="s3-5"><title>Animal</title><p>Mouse serum was obtained from male and female C57BL6J jcl mice. Mice were maintained at 22°C under a 12:12 hr light-dark cycle (lights on from 8:00 AM to 8:00 PM). The experimental protocol was approved as No. 28-072-023 by the Ethics Review Committee for Animal Experimentation of Osaka University School of Medicine. This study also conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.</p></sec><sec id="s3-6"><title>Binding study</title><p>Adiponectin binding studies were performed using serum as the source of adiponectin in situ without any processing. Cells were treated with the indicated concentrations of serum in serum-free DMEM at 4°C for 1 hr and then washed with serum-free DMEM three times. NZ-1 binding was performed by incubating cells with 1.0 μg/mL NZ-1 in DMEM containing 0.2%BSA at 4°C for 1 hr and washed with serum-free DMEM three times. Cell lysates were combined with Laemmli sample buffer for SDS-PAGE and heated at 98°C for 5 min or combined with native-page buffer (<xref ref-type="bibr" rid="bib25">Suzuki et al., 2007</xref>).</p></sec><sec id="s3-7"><title>Adiponectin concentration</title><p>Adiponectin concentrations in sample preparations were measured by ELISA (Otsuka Pharmaceutical Co.).</p></sec><sec id="s3-8"><title>Western blotting</title><p>Whole cell lysates were loaded onto 4–20% gradient SDS-PAGE gels (Bio-Rad) and transferred to nitrocellulose membranes. Membranes were blocked with PVDF Blocking Reagent for the Can Get signal (TOYOBO), incubated with primary antibodies using Can Get signal solution 1 (TOYOBO) at 4°C overnight, and then incubated with secondary antibodies conjugated with HRP using Can Get signal solution 2 (TOYOBO) at room temperature (RT) for 60 min. Chemiluminescence signals developed with Chemi-Lumi One Super (Nacalai Tesque) were visualized by ChemiDoc Touch and quantitated using Image Lab software (Bio-Rad). A native-PAGE analysis of the multimer composition of adiponectin was performed according to the method described (<xref ref-type="bibr" rid="bib25">Suzuki et al., 2007</xref>).</p></sec><sec id="s3-9"><title>Cell surface protein biotinylation</title><p>Cell surface protein biotinylation and subsequent isolation were performed using the Cell Surface Biotinylation Kit (Pierce) according to the instructions provided by the manufacturer.</p></sec><sec id="s3-10"><title>Immunofluorescence staining</title><p>Cells on coverslips were fixed with periodate-lysine-paraformaldehyde (PLP) for 30 min and incubated with 3% w/v BSA and 0.3% w/v Triton X-100 in Dulbecco’s phosphate-buffered saline without calcium or magnesium (PBS) for 60 min. Cells were then incubated with 10 μg/mL NZ-1 at 4°C overnight and then incubated with an Alexa-Fluor 488 secondary antibody at RT for 60 min. Cell nuclei were counterstained with DAPI. A microscopy analysis was performed using an Olympus FV1000D confocal laser scanning microscope system (Olympus).</p></sec><sec id="s3-11"><title>Statistical analysis</title><p>Values were expressed as the mean ± SEM. Differences between variables were compared using the Student’s t-test. The probability (P) values of &lt;0.05 were considered to be significant.</p></sec><sec id="s3-12"><title>Data and software availability</title><p>All data were deposited in Dryad at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.82557c0">https://doi.org/10.5061/dryad.82557c0</ext-link>.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors thank the staff of the Center of Medical Research and Education, Graduate School of Medicine Osaka University, for their excellent technical support. This work was supported in part by a Grant-in-Aid for Scientific Research (C) #16K09802 (to SK), a Grant-in-Aid for Scientific Research (C) #16K09801 (to NM), and a Grant-in-Aid for Scientific Research (B) #15H04853 (to IS), the Uehara Memorial Foundation, as well as CREST and JST (to IS). The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Software, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing, Performed biochemical and cellular experiments</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Software, Validation, Visualization, Methodology, Writing—review and editing, Cloned the cDNAs of adiponectin receptors</p></fn><fn fn-type="con" id="con3"><p>Data curation, Supervision, Funding acquisition, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Supervision, Funding acquisition, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The experimental protocol was approved as No. 28-072-023 by the Ethics Review Committee for Animal Experimentation of Osaka University School of Medicine. This study also conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.48675.007</object-id><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-48675-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s6" sec-type="data-availability"><title>Data availability</title><p>All data were deposited in Dryad at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.82557c0">https://doi.org/10.5061/dryad.82557c0</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kita</surname><given-names>S</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Maeda</surname><given-names>N</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Data from: Native adiponectin in serum binds to cells expressing T-cadherin, but not AdipoRs or calreticulin</data-title><source>Dryad Digital Repository</source><pub-id assigning-authority="Dryad" pub-id-type="doi">10.5061/dryad.82557c0</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buniello</surname> <given-names>A</given-names></name><name><surname>MacArthur</surname> <given-names>JAL</given-names></name><name><surname>Cerezo</surname> <given-names>M</given-names></name><name><surname>Harris</surname> <given-names>LW</given-names></name><name><surname>Hayhurst</surname> <given-names>J</given-names></name><name><surname>Malangone</surname> <given-names>C</given-names></name><name><surname>McMahon</surname> <given-names>A</given-names></name><name><surname>Morales</surname> <given-names>J</given-names></name><name><surname>Mountjoy</surname> <given-names>E</given-names></name><name><surname>Sollis</surname> <given-names>E</given-names></name><name><surname>Suveges</surname> <given-names>D</given-names></name><name><surname>Vrousgou</surname> <given-names>O</given-names></name><name><surname>Whetzel</surname> <given-names>PL</given-names></name><name><surname>Amode</surname> <given-names>R</given-names></name><name><surname>Guillen</surname> <given-names>JA</given-names></name><name><surname>Riat</surname> <given-names>HS</given-names></name><name><surname>Trevanion</surname> <given-names>SJ</given-names></name><name><surname>Hall</surname> <given-names>P</given-names></name><name><surname>Junkins</surname> <given-names>H</given-names></name><name><surname>Flicek</surname> <given-names>P</given-names></name><name><surname>Burdett</surname> <given-names>T</given-names></name><name><surname>Hindorff</surname> <given-names>LA</given-names></name><name><surname>Cunningham</surname> <given-names>F</given-names></name><name><surname>Parkinson</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D1005</fpage><lpage>D1012</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1120</pub-id><pub-id pub-id-type="pmid">30445434</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname> <given-names>CM</given-names></name><name><surname>Lin</surname> <given-names>TH</given-names></name><name><surname>Chen</surname> <given-names>JW</given-names></name><name><surname>Leu</surname> <given-names>HB</given-names></name><name><surname>Yang</surname> <given-names>HC</given-names></name><name><surname>Ho</surname> <given-names>HY</given-names></name><name><surname>Ting</surname> <given-names>CT</given-names></name><name><surname>Sheu</surname> <given-names>SH</given-names></name><name><surname>Tsai</surname> <given-names>WC</given-names></name><name><surname>Chen</surname> <given-names>JH</given-names></name><name><surname>Lin</surname> <given-names>SJ</given-names></name><name><surname>Chen</surname> <given-names>YT</given-names></name><name><surname>Pan</surname> <given-names>WH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardiometabolic outcomes</article-title><source>Diabetes</source><volume>60</volume><fpage>2417</fpage><lpage>2423</lpage><pub-id pub-id-type="doi">10.2337/db10-1321</pub-id><pub-id pub-id-type="pmid">21771975</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciatto</surname> <given-names>C</given-names></name><name><surname>Bahna</surname> <given-names>F</given-names></name><name><surname>Zampieri</surname> <given-names>N</given-names></name><name><surname>VanSteenhouse</surname> <given-names>HC</given-names></name><name><surname>Katsamba</surname> <given-names>PS</given-names></name><name><surname>Ahlsen</surname> <given-names>G</given-names></name><name><surname>Harrison</surname> <given-names>OJ</given-names></name><name><surname>Brasch</surname> <given-names>J</given-names></name><name><surname>Jin</surname> <given-names>X</given-names></name><name><surname>Posy</surname> <given-names>S</given-names></name><name><surname>Vendome</surname> <given-names>J</given-names></name><name><surname>Ranscht</surname> <given-names>B</given-names></name><name><surname>Jessell</surname> <given-names>TM</given-names></name><name><surname>Honig</surname> <given-names>B</given-names></name><name><surname>Shapiro</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>T-cadherin structures reveal a novel adhesive binding mechanism</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>17</volume><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1781</pub-id><pub-id pub-id-type="pmid">20190755</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dastani</surname> <given-names>Z</given-names></name><name><surname>Hivert</surname> <given-names>MF</given-names></name><name><surname>Timpson</surname> <given-names>N</given-names></name><name><surname>Perry</surname> <given-names>JR</given-names></name><name><surname>Yuan</surname> <given-names>X</given-names></name><name><surname>Scott</surname> <given-names>RA</given-names></name><name><surname>Henneman</surname> <given-names>P</given-names></name><name><surname>Heid</surname> <given-names>IM</given-names></name><name><surname>Kizer</surname> <given-names>JR</given-names></name><name><surname>Lyytikäinen</surname> <given-names>LP</given-names></name><name><surname>Fuchsberger</surname> <given-names>C</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Morris</surname> <given-names>AP</given-names></name><name><surname>Small</surname> <given-names>K</given-names></name><name><surname>Isaacs</surname> <given-names>A</given-names></name><name><surname>Beekman</surname> <given-names>M</given-names></name><name><surname>Coassin</surname> <given-names>S</given-names></name><name><surname>Lohman</surname> <given-names>K</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Kanoni</surname> <given-names>S</given-names></name><name><surname>Pankow</surname> <given-names>JS</given-names></name><name><surname>Uh</surname> <given-names>HW</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Bidulescu</surname> <given-names>A</given-names></name><name><surname>Rasmussen-Torvik</surname> <given-names>LJ</given-names></name><name><surname>Greenwood</surname> <given-names>CM</given-names></name><name><surname>Ladouceur</surname> <given-names>M</given-names></name><name><surname>Grimsby</surname> <given-names>J</given-names></name><name><surname>Manning</surname> <given-names>AK</given-names></name><name><surname>Liu</surname> <given-names>CT</given-names></name><name><surname>Kooner</surname> <given-names>J</given-names></name><name><surname>Mooser</surname> <given-names>VE</given-names></name><name><surname>Vollenweider</surname> <given-names>P</given-names></name><name><surname>Kapur</surname> <given-names>KA</given-names></name><name><surname>Chambers</surname> <given-names>J</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Frants</surname> <given-names>R</given-names></name><name><surname>Willems-Vandijk</surname> <given-names>K</given-names></name><name><surname>Oostra</surname> <given-names>BA</given-names></name><name><surname>Willems</surname> <given-names>SM</given-names></name><name><surname>Lamina</surname> <given-names>C</given-names></name><name><surname>Winkler</surname> <given-names>TW</given-names></name><name><surname>Psaty</surname> <given-names>BM</given-names></name><name><surname>Tracy</surname> <given-names>RP</given-names></name><name><surname>Brody</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>I</given-names></name><name><surname>Viikari</surname> <given-names>J</given-names></name><name><surname>Kähönen</surname> <given-names>M</given-names></name><name><surname>Pramstaller</surname> <given-names>PP</given-names></name><name><surname>Evans</surname> <given-names>DM</given-names></name><name><surname>St Pourcain</surname> <given-names>B</given-names></name><name><surname>Sattar</surname> <given-names>N</given-names></name><name><surname>Wood</surname> <given-names>AR</given-names></name><name><surname>Bandinelli</surname> <given-names>S</given-names></name><name><surname>Carlson</surname> <given-names>OD</given-names></name><name><surname>Egan</surname> <given-names>JM</given-names></name><name><surname>Böhringer</surname> <given-names>S</given-names></name><name><surname>van Heemst</surname> <given-names>D</given-names></name><name><surname>Kedenko</surname> <given-names>L</given-names></name><name><surname>Kristiansson</surname> <given-names>K</given-names></name><name><surname>Nuotio</surname> <given-names>ML</given-names></name><name><surname>Loo</surname> <given-names>BM</given-names></name><name><surname>Harris</surname> <given-names>T</given-names></name><name><surname>Garcia</surname> <given-names>M</given-names></name><name><surname>Kanaya</surname> <given-names>A</given-names></name><name><surname>Haun</surname> <given-names>M</given-names></name><name><surname>Klopp</surname> <given-names>N</given-names></name><name><surname>Wichmann</surname> <given-names>HE</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Katsareli</surname> <given-names>E</given-names></name><name><surname>Couper</surname> <given-names>DJ</given-names></name><name><surname>Duncan</surname> <given-names>BB</given-names></name><name><surname>Kloppenburg</surname> <given-names>M</given-names></name><name><surname>Adair</surname> <given-names>LS</given-names></name><name><surname>Borja</surname> <given-names>JB</given-names></name><name><surname>Wilson</surname> <given-names>JG</given-names></name><name><surname>Musani</surname> <given-names>S</given-names></name><name><surname>Guo</surname> <given-names>X</given-names></name><name><surname>Johnson</surname> <given-names>T</given-names></name><name><surname>Semple</surname> <given-names>R</given-names></name><name><surname>Teslovich</surname> <given-names>TM</given-names></name><name><surname>Allison</surname> <given-names>MA</given-names></name><name><surname>Redline</surname> <given-names>S</given-names></name><name><surname>Buxbaum</surname> <given-names>SG</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Meulenbelt</surname> <given-names>I</given-names></name><name><surname>Ballantyne</surname> <given-names>CM</given-names></name><name><surname>Dedoussis</surname> <given-names>GV</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Paulweber</surname> <given-names>B</given-names></name><name><surname>Spector</surname> <given-names>TD</given-names></name><name><surname>Slagboom</surname> <given-names>PE</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Jula</surname> <given-names>A</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Raitakari</surname> <given-names>O</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Eriksson</surname> <given-names>JG</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Hicks</surname> <given-names>AA</given-names></name><name><surname>Lehtimäki</surname> <given-names>T</given-names></name><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>Siscovick</surname> <given-names>DS</given-names></name><name><surname>Kronenberg</surname> <given-names>F</given-names></name><name><surname>van Duijn</surname> <given-names>C</given-names></name><name><surname>Loos</surname> <given-names>RJ</given-names></name><name><surname>Waterworth</surname> <given-names>DM</given-names></name><name><surname>Meigs</surname> <given-names>JB</given-names></name><name><surname>Dupuis</surname> <given-names>J</given-names></name><name><surname>Richards</surname> <given-names>JB</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Scott</surname> <given-names>LJ</given-names></name><name><surname>Steinthorsdottir</surname> <given-names>V</given-names></name><name><surname>Dina</surname> <given-names>C</given-names></name><name><surname>Welch</surname> <given-names>RP</given-names></name><name><surname>Zeggini</surname> <given-names>E</given-names></name><name><surname>Huth</surname> <given-names>C</given-names></name><name><surname>Aulchenko</surname> <given-names>YS</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>McCulloch</surname> <given-names>LJ</given-names></name><name><surname>Ferreira</surname> <given-names>T</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Amin</surname> <given-names>N</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Willer</surname> <given-names>CJ</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>McCarroll</surname> <given-names>SA</given-names></name><name><surname>Hofmann</surname> <given-names>OM</given-names></name><name><surname>Segrè</surname> <given-names>AV</given-names></name><name><surname>van Hoek</surname> <given-names>M</given-names></name><name><surname>Navarro</surname> <given-names>P</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Balkau</surname> <given-names>B</given-names></name><name><surname>Benediktsson</surname> <given-names>R</given-names></name><name><surname>Bennett</surname> <given-names>AJ</given-names></name><name><surname>Blagieva</surname> <given-names>R</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Boström</surname> <given-names>KB</given-names></name><name><surname>Bravenboer</surname> <given-names>B</given-names></name><name><surname>Bumpstead</surname> <given-names>S</given-names></name><name><surname>Burtt</surname> <given-names>NP</given-names></name><name><surname>Charpentier</surname> <given-names>G</given-names></name><name><surname>Chines</surname> <given-names>PS</given-names></name><name><surname>Cornelis</surname> <given-names>M</given-names></name><name><surname>Crawford</surname> <given-names>G</given-names></name><name><surname>Doney</surname> <given-names>AS</given-names></name><name><surname>Elliott</surname> <given-names>KS</given-names></name><name><surname>Elliott</surname> <given-names>AL</given-names></name><name><surname>Erdos</surname> <given-names>MR</given-names></name><name><surname>Fox</surname> <given-names>CS</given-names></name><name><surname>Franklin</surname> <given-names>CS</given-names></name><name><surname>Ganser</surname> <given-names>M</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Green</surname> <given-names>T</given-names></name><name><surname>Griffin</surname> <given-names>S</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>Guiducci</surname> <given-names>C</given-names></name><name><surname>Hadjadj</surname> <given-names>S</given-names></name><name><surname>Hassanali</surname> <given-names>N</given-names></name><name><surname>Herder</surname> <given-names>C</given-names></name><name><surname>Isomaa</surname> <given-names>B</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Johnson</surname> <given-names>PR</given-names></name><name><surname>Jørgensen</surname> <given-names>T</given-names></name><name><surname>Kao</surname> <given-names>WH</given-names></name><name><surname>Kong</surname> <given-names>A</given-names></name><name><surname>Kraft</surname> <given-names>P</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Lauritzen</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Lieverse</surname> <given-names>A</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Lyssenko</surname> <given-names>V</given-names></name><name><surname>Marre</surname> <given-names>M</given-names></name><name><surname>Meitinger</surname> <given-names>T</given-names></name><name><surname>Midthjell</surname> <given-names>K</given-names></name><name><surname>Morken</surname> <given-names>MA</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Owen</surname> <given-names>KR</given-names></name><name><surname>Payne</surname> <given-names>F</given-names></name><name><surname>Petersen</surname> <given-names>AK</given-names></name><name><surname>Platou</surname> <given-names>C</given-names></name><name><surname>Proença</surname> <given-names>C</given-names></name><name><surname>Prokopenko</surname> <given-names>I</given-names></name><name><surname>Rathmann</surname> <given-names>W</given-names></name><name><surname>Rayner</surname> <given-names>NW</given-names></name><name><surname>Robertson</surname> <given-names>NR</given-names></name><name><surname>Rocheleau</surname> <given-names>G</given-names></name><name><surname>Roden</surname> <given-names>M</given-names></name><name><surname>Sampson</surname> <given-names>MJ</given-names></name><name><surname>Saxena</surname> <given-names>R</given-names></name><name><surname>Shields</surname> <given-names>BM</given-names></name><name><surname>Shrader</surname> <given-names>P</given-names></name><name><surname>Sigurdsson</surname> <given-names>G</given-names></name><name><surname>Sparsø</surname> <given-names>T</given-names></name><name><surname>Strassburger</surname> <given-names>K</given-names></name><name><surname>Stringham</surname> <given-names>HM</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Swift</surname> <given-names>AJ</given-names></name><name><surname>Thorand</surname> <given-names>B</given-names></name><name><surname>Tichet</surname> <given-names>J</given-names></name><name><surname>Tuomi</surname> <given-names>T</given-names></name><name><surname>van Dam</surname> <given-names>RM</given-names></name><name><surname>van Haeften</surname> <given-names>TW</given-names></name><name><surname>van Herpt</surname> <given-names>T</given-names></name><name><surname>van Vliet-Ostaptchouk</surname> <given-names>JV</given-names></name><name><surname>Walters</surname> <given-names>GB</given-names></name><name><surname>Weedon</surname> <given-names>MN</given-names></name><name><surname>Wijmenga</surname> <given-names>C</given-names></name><name><surname>Witteman</surname> <given-names>J</given-names></name><name><surname>Bergman</surname> <given-names>RN</given-names></name><name><surname>Cauchi</surname> <given-names>S</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Gloyn</surname> <given-names>AL</given-names></name><name><surname>Gyllensten</surname> <given-names>U</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Hide</surname> <given-names>WA</given-names></name><name><surname>Hitman</surname> <given-names>GA</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Hunter</surname> <given-names>DJ</given-names></name><name><surname>Hveem</surname> <given-names>K</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Rudan</surname> <given-names>I</given-names></name><name><surname>Sijbrands</surname> <given-names>E</given-names></name><name><surname>Stein</surname> <given-names>LD</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Uitterlinden</surname> <given-names>A</given-names></name><name><surname>Walker</surname> <given-names>M</given-names></name><name><surname>Watanabe</surname> <given-names>RM</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Boehm</surname> <given-names>BO</given-names></name><name><surname>Campbell</surname> <given-names>H</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Hattersley</surname> <given-names>AT</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Groop</surname> <given-names>L</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Soranzo</surname> <given-names>N</given-names></name><name><surname>Wheeler</surname> <given-names>E</given-names></name><name><surname>Glazer</surname> <given-names>NL</given-names></name><name><surname>Bouatia-Naji</surname> <given-names>N</given-names></name><name><surname>Mägi</surname> <given-names>R</given-names></name><name><surname>Randall</surname> <given-names>J</given-names></name><name><surname>Elliott</surname> <given-names>P</given-names></name><name><surname>Rybin</surname> <given-names>D</given-names></name><name><surname>Dehghan</surname> <given-names>A</given-names></name><name><surname>Hottenga</surname> <given-names>JJ</given-names></name><name><surname>Song</surname> <given-names>K</given-names></name><name><surname>Goel</surname> <given-names>A</given-names></name><name><surname>Lajunen</surname> <given-names>T</given-names></name><name><surname>Doney</surname> <given-names>A</given-names></name><name><surname>Cavalcanti-Proença</surname> <given-names>C</given-names></name><name><surname>Kumari</surname> <given-names>M</given-names></name><name><surname>Timpson</surname> <given-names>NJ</given-names></name><name><surname>Zabena</surname> <given-names>C</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>An</surname> <given-names>P</given-names></name><name><surname>O'Connell</surname> <given-names>J</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Elliott</surname> <given-names>A</given-names></name><name><surname>McCarroll</surname> <given-names>SA</given-names></name><name><surname>Roccasecca</surname> <given-names>RM</given-names></name><name><surname>Pattou</surname> <given-names>F</given-names></name><name><surname>Sethupathy</surname> <given-names>P</given-names></name><name><surname>Ariyurek</surname> <given-names>Y</given-names></name><name><surname>Barter</surname> <given-names>P</given-names></name><name><surname>Beilby</surname> <given-names>JP</given-names></name><name><surname>Ben-Shlomo</surname> <given-names>Y</given-names></name><name><surname>Bergmann</surname> <given-names>S</given-names></name><name><surname>Bochud</surname> <given-names>M</given-names></name><name><surname>Bonnefond</surname> <given-names>A</given-names></name><name><surname>Borch-Johnsen</surname> <given-names>K</given-names></name><name><surname>Böttcher</surname> <given-names>Y</given-names></name><name><surname>Brunner</surname> <given-names>E</given-names></name><name><surname>Bumpstead</surname> <given-names>SJ</given-names></name><name><surname>Chen</surname> <given-names>YD</given-names></name><name><surname>Chines</surname> <given-names>P</given-names></name><name><surname>Clarke</surname> <given-names>R</given-names></name><name><surname>Coin</surname> <given-names>LJ</given-names></name><name><surname>Cooper</surname> <given-names>MN</given-names></name><name><surname>Crisponi</surname> <given-names>L</given-names></name><name><surname>Day</surname> <given-names>IN</given-names></name><name><surname>de Geus</surname> <given-names>EJ</given-names></name><name><surname>Delplanque</surname> <given-names>J</given-names></name><name><surname>Fedson</surname> <given-names>AC</given-names></name><name><surname>Fischer-Rosinsky</surname> <given-names>A</given-names></name><name><surname>Forouhi</surname> <given-names>NG</given-names></name><name><surname>Franzosi</surname> <given-names>MG</given-names></name><name><surname>Galan</surname> <given-names>P</given-names></name><name><surname>Goodarzi</surname> <given-names>MO</given-names></name><name><surname>Graessler</surname> <given-names>J</given-names></name><name><surname>Grundy</surname> <given-names>S</given-names></name><name><surname>Gwilliam</surname> <given-names>R</given-names></name><name><surname>Hallmans</surname> <given-names>G</given-names></name><name><surname>Hammond</surname> <given-names>N</given-names></name><name><surname>Han</surname> <given-names>X</given-names></name><name><surname>Hartikainen</surname> <given-names>AL</given-names></name><name><surname>Hayward</surname> <given-names>C</given-names></name><name><surname>Heath</surname> <given-names>SC</given-names></name><name><surname>Hercberg</surname> <given-names>S</given-names></name><name><surname>Hillman</surname> <given-names>DR</given-names></name><name><surname>Hingorani</surname> <given-names>AD</given-names></name><name><surname>Hui</surname> <given-names>J</given-names></name><name><surname>Hung</surname> <given-names>J</given-names></name><name><surname>Kaakinen</surname> <given-names>M</given-names></name><name><surname>Kaprio</surname> <given-names>J</given-names></name><name><surname>Kesaniemi</surname> <given-names>YA</given-names></name><name><surname>Kivimaki</surname> <given-names>M</given-names></name><name><surname>Knight</surname> <given-names>B</given-names></name><name><surname>Koskinen</surname> <given-names>S</given-names></name><name><surname>Kovacs</surname> <given-names>P</given-names></name><name><surname>Kyvik</surname> <given-names>KO</given-names></name><name><surname>Lathrop</surname> <given-names>GM</given-names></name><name><surname>Lawlor</surname> <given-names>DA</given-names></name><name><surname>Le Bacquer</surname> <given-names>O</given-names></name><name><surname>Lecoeur</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Mahley</surname> <given-names>R</given-names></name><name><surname>Mangino</surname> <given-names>M</given-names></name><name><surname>Martínez-Larrad</surname> <given-names>MT</given-names></name><name><surname>McAteer</surname> <given-names>JB</given-names></name><name><surname>McPherson</surname> <given-names>R</given-names></name><name><surname>Meisinger</surname> <given-names>C</given-names></name><name><surname>Melzer</surname> <given-names>D</given-names></name><name><surname>Meyre</surname> <given-names>D</given-names></name><name><surname>Mitchell</surname> <given-names>BD</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Naitza</surname> <given-names>S</given-names></name><name><surname>Neville</surname> <given-names>MJ</given-names></name><name><surname>Orrù</surname> <given-names>M</given-names></name><name><surname>Pakyz</surname> <given-names>R</given-names></name><name><surname>Paolisso</surname> <given-names>G</given-names></name><name><surname>Pattaro</surname> <given-names>C</given-names></name><name><surname>Pearson</surname> <given-names>D</given-names></name><name><surname>Peden</surname> <given-names>JF</given-names></name><name><surname>Pedersen</surname> <given-names>NL</given-names></name><name><surname>Pfeiffer</surname> <given-names>AF</given-names></name><name><surname>Pichler</surname> <given-names>I</given-names></name><name><surname>Polasek</surname> <given-names>O</given-names></name><name><surname>Posthuma</surname> <given-names>D</given-names></name><name><surname>Potter</surname> <given-names>SC</given-names></name><name><surname>Pouta</surname> <given-names>A</given-names></name><name><surname>Province</surname> <given-names>MA</given-names></name><name><surname>Rayner</surname> <given-names>NW</given-names></name><name><surname>Rice</surname> <given-names>K</given-names></name><name><surname>Ripatti</surname> <given-names>S</given-names></name><name><surname>Rivadeneira</surname> <given-names>F</given-names></name><name><surname>Rolandsson</surname> <given-names>O</given-names></name><name><surname>Sandbaek</surname> <given-names>A</given-names></name><name><surname>Sandhu</surname> <given-names>M</given-names></name><name><surname>Sanna</surname> <given-names>S</given-names></name><name><surname>Sayer</surname> <given-names>AA</given-names></name><name><surname>Scheet</surname> <given-names>P</given-names></name><name><surname>Seedorf</surname> <given-names>U</given-names></name><name><surname>Sharp</surname> <given-names>SJ</given-names></name><name><surname>Shields</surname> <given-names>B</given-names></name><name><surname>Sigurðsson</surname> <given-names>G</given-names></name><name><surname>Sijbrands</surname> <given-names>EJ</given-names></name><name><surname>Silveira</surname> <given-names>A</given-names></name><name><surname>Simpson</surname> <given-names>L</given-names></name><name><surname>Singleton</surname> <given-names>A</given-names></name><name><surname>Smith</surname> <given-names>NL</given-names></name><name><surname>Sovio</surname> <given-names>U</given-names></name><name><surname>Swift</surname> <given-names>A</given-names></name><name><surname>Syddall</surname> <given-names>H</given-names></name><name><surname>Syvänen</surname> <given-names>AC</given-names></name><name><surname>Tönjes</surname> <given-names>A</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>van Dijk</surname> <given-names>KW</given-names></name><name><surname>Varma</surname> <given-names>D</given-names></name><name><surname>Visvikis-Siest</surname> <given-names>S</given-names></name><name><surname>Vitart</surname> <given-names>V</given-names></name><name><surname>Vogelzangs</surname> <given-names>N</given-names></name><name><surname>Waeber</surname> <given-names>G</given-names></name><name><surname>Wagner</surname> <given-names>PJ</given-names></name><name><surname>Walley</surname> <given-names>A</given-names></name><name><surname>Ward</surname> <given-names>KL</given-names></name><name><surname>Watkins</surname> <given-names>H</given-names></name><name><surname>Wild</surname> <given-names>SH</given-names></name><name><surname>Willemsen</surname> <given-names>G</given-names></name><name><surname>Witteman</surname> <given-names>JC</given-names></name><name><surname>Yarnell</surname> <given-names>JW</given-names></name><name><surname>Zelenika</surname> <given-names>D</given-names></name><name><surname>Zethelius</surname> <given-names>B</given-names></name><name><surname>Zhai</surname> <given-names>G</given-names></name><name><surname>Zhao</surname> <given-names>JH</given-names></name><name><surname>Zillikens</surname> <given-names>MC</given-names></name><name><surname>Borecki</surname> <given-names>IB</given-names></name><name><surname>Meneton</surname> <given-names>P</given-names></name><name><surname>Magnusson</surname> <given-names>PK</given-names></name><name><surname>Nathan</surname> <given-names>DM</given-names></name><name><surname>Williams</surname> <given-names>GH</given-names></name><name><surname>Silander</surname> <given-names>K</given-names></name><name><surname>Bornstein</surname> <given-names>SR</given-names></name><name><surname>Schwarz</surname> <given-names>P</given-names></name><name><surname>Spranger</surname> <given-names>J</given-names></name><name><surname>Karpe</surname> <given-names>F</given-names></name><name><surname>Shuldiner</surname> <given-names>AR</given-names></name><name><surname>Cooper</surname> <given-names>C</given-names></name><name><surname>Serrano-Ríos</surname> <given-names>M</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Palmer</surname> <given-names>LJ</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name><name><surname>Franks</surname> <given-names>PW</given-names></name><name><surname>Ebrahim</surname> <given-names>S</given-names></name><name><surname>Marmot</surname> <given-names>M</given-names></name><name><surname>Kao</surname> <given-names>WH</given-names></name><name><surname>Pramstaller</surname> <given-names>PP</given-names></name><name><surname>Wright</surname> <given-names>AF</given-names></name><name><surname>Stumvoll</surname> <given-names>M</given-names></name><name><surname>Hamsten</surname> <given-names>A</given-names></name><name><surname>Buchanan</surname> <given-names>TA</given-names></name><name><surname>Valle</surname> <given-names>TT</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Penninx</surname> <given-names>BW</given-names></name><name><surname>Boomsma</surname> <given-names>DI</given-names></name><name><surname>Cao</surname> <given-names>A</given-names></name><name><surname>Scuteri</surname> <given-names>A</given-names></name><name><surname>Schlessinger</surname> <given-names>D</given-names></name><name><surname>Uda</surname> <given-names>M</given-names></name><name><surname>Ruokonen</surname> <given-names>A</given-names></name><name><surname>Jarvelin</surname> <given-names>MR</given-names></name><name><surname>Peltonen</surname> <given-names>L</given-names></name><name><surname>Mooser</surname> <given-names>V</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Musunuru</surname> <given-names>K</given-names></name><name><surname>Smith</surname> <given-names>AV</given-names></name><name><surname>Edmondson</surname> <given-names>AC</given-names></name><name><surname>Stylianou</surname> <given-names>IM</given-names></name><name><surname>Koseki</surname> <given-names>M</given-names></name><name><surname>Pirruccello</surname> <given-names>JP</given-names></name><name><surname>Chasman</surname> <given-names>DI</given-names></name><name><surname>Johansen</surname> <given-names>CT</given-names></name><name><surname>Fouchier</surname> <given-names>SW</given-names></name><name><surname>Peloso</surname> <given-names>GM</given-names></name><name><surname>Barbalic</surname> <given-names>M</given-names></name><name><surname>Ricketts</surname> <given-names>SL</given-names></name><name><surname>Bis</surname> <given-names>JC</given-names></name><name><surname>Feitosa</surname> <given-names>MF</given-names></name><name><surname>Orho-Melander</surname> <given-names>M</given-names></name><name><surname>Melander</surname> <given-names>O</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Cho</surname> <given-names>YS</given-names></name><name><surname>Go</surname> <given-names>MJ</given-names></name><name><surname>Kim</surname> <given-names>YJ</given-names></name><name><surname>Lee</surname> <given-names>JY</given-names></name><name><surname>Park</surname> <given-names>T</given-names></name><name><surname>Kim</surname> <given-names>K</given-names></name><name><surname>Sim</surname> <given-names>X</given-names></name><name><surname>Ong</surname> <given-names>RT</given-names></name><name><surname>Croteau-Chonka</surname> <given-names>DC</given-names></name><name><surname>Lange</surname> <given-names>LA</given-names></name><name><surname>Smith</surname> <given-names>JD</given-names></name><name><surname>Ziegler</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Zee</surname> <given-names>RY</given-names></name><name><surname>Whitfield</surname> <given-names>JB</given-names></name><name><surname>Thompson</surname> <given-names>JR</given-names></name><name><surname>Surakka</surname> <given-names>I</given-names></name><name><surname>Spector</surname> <given-names>TD</given-names></name><name><surname>Smit</surname> <given-names>JH</given-names></name><name><surname>Sinisalo</surname> <given-names>J</given-names></name><name><surname>Scott</surname> <given-names>J</given-names></name><name><surname>Saharinen</surname> <given-names>J</given-names></name><name><surname>Sabatti</surname> <given-names>C</given-names></name><name><surname>Rose</surname> <given-names>LM</given-names></name><name><surname>Roberts</surname> <given-names>R</given-names></name><name><surname>Rieder</surname> <given-names>M</given-names></name><name><surname>Parker</surname> <given-names>AN</given-names></name><name><surname>Pare</surname> <given-names>G</given-names></name><name><surname>O'Donnell</surname> <given-names>CJ</given-names></name><name><surname>Nieminen</surname> <given-names>MS</given-names></name><name><surname>Nickerson</surname> <given-names>DA</given-names></name><name><surname>Montgomery</surname> <given-names>GW</given-names></name><name><surname>McArdle</surname> <given-names>W</given-names></name><name><surname>Masson</surname> <given-names>D</given-names></name><name><surname>Martin</surname> <given-names>NG</given-names></name><name><surname>Marroni</surname> <given-names>F</given-names></name><name><surname>Lucas</surname> <given-names>G</given-names></name><name><surname>Luben</surname> <given-names>R</given-names></name><name><surname>Lokki</surname> <given-names>ML</given-names></name><name><surname>Lettre</surname> <given-names>G</given-names></name><name><surname>Launer</surname> <given-names>LJ</given-names></name><name><surname>Lakatta</surname> <given-names>EG</given-names></name><name><surname>Laaksonen</surname> <given-names>R</given-names></name><name><surname>Kyvik</surname> <given-names>KO</given-names></name><name><surname>König</surname> <given-names>IR</given-names></name><name><surname>Khaw</surname> <given-names>KT</given-names></name><name><surname>Kaplan</surname> <given-names>LM</given-names></name><name><surname>Johansson</surname> <given-names>Å</given-names></name><name><surname>Janssens</surname> <given-names>AC</given-names></name><name><surname>Igl</surname> <given-names>W</given-names></name><name><surname>Hovingh</surname> <given-names>GK</given-names></name><name><surname>Hengstenberg</surname> <given-names>C</given-names></name><name><surname>Havulinna</surname> <given-names>AS</given-names></name><name><surname>Hastie</surname> <given-names>ND</given-names></name><name><surname>Harris</surname> <given-names>TB</given-names></name><name><surname>Haritunians</surname> <given-names>T</given-names></name><name><surname>Hall</surname> <given-names>AS</given-names></name><name><surname>Groop</surname> <given-names>LC</given-names></name><name><surname>Gonzalez</surname> <given-names>E</given-names></name><name><surname>Freimer</surname> <given-names>NB</given-names></name><name><surname>Erdmann</surname> <given-names>J</given-names></name><name><surname>Ejebe</surname> <given-names>KG</given-names></name><name><surname>Döring</surname> <given-names>A</given-names></name><name><surname>Dominiczak</surname> <given-names>AF</given-names></name><name><surname>Demissie</surname> <given-names>S</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>de Faire</surname> <given-names>U</given-names></name><name><surname>Crawford</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>YD</given-names></name><name><surname>Caulfield</surname> <given-names>MJ</given-names></name><name><surname>Boekholdt</surname> <given-names>SM</given-names></name><name><surname>Assimes</surname> <given-names>TL</given-names></name><name><surname>Quertermous</surname> <given-names>T</given-names></name><name><surname>Seielstad</surname> <given-names>M</given-names></name><name><surname>Wong</surname> <given-names>TY</given-names></name><name><surname>Tai</surname> <given-names>ES</given-names></name><name><surname>Feranil</surname> <given-names>AB</given-names></name><name><surname>Kuzawa</surname> <given-names>CW</given-names></name><name><surname>Taylor</surname> <given-names>HA</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Holm</surname> <given-names>H</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Krauss</surname> <given-names>RM</given-names></name><name><surname>Ordovas</surname> <given-names>JM</given-names></name><name><surname>Munroe</surname> <given-names>PB</given-names></name><name><surname>Kooner</surname> <given-names>JS</given-names></name><name><surname>Tall</surname> <given-names>AR</given-names></name><name><surname>Hegele</surname> <given-names>RA</given-names></name><name><surname>Kastelein</surname> <given-names>JJ</given-names></name><name><surname>Schadt</surname> <given-names>EE</given-names></name><name><surname>Strachan</surname> <given-names>DP</given-names></name><name><surname>Reilly</surname> <given-names>MP</given-names></name><name><surname>Samani</surname> <given-names>NJ</given-names></name><name><surname>Schunkert</surname> <given-names>H</given-names></name><name><surname>Cupples</surname> <given-names>LA</given-names></name><name><surname>Sandhu</surname> <given-names>MS</given-names></name><name><surname>Ridker</surname> <given-names>PM</given-names></name><name><surname>Rader</surname> <given-names>DJ</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name><collab>DIAGRAM+ Consortium</collab><collab>MAGIC Consortium</collab><collab>GLGC Investigators</collab><collab>MuTHER Consortium</collab><collab>DIAGRAM Consortium</collab><collab>GIANT Consortium</collab><collab>Global B Pgen Consortium</collab><collab>Procardis Consortium</collab><collab>MAGIC investigators</collab><collab>GLGC Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals</article-title><source>PLOS Genetics</source><volume>8</volume><elocation-id>e1002607</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002607</pub-id><pub-id pub-id-type="pmid">22479202</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denzel</surname> <given-names>MS</given-names></name><name><surname>Scimia</surname> <given-names>MC</given-names></name><name><surname>Zumstein</surname> <given-names>PM</given-names></name><name><surname>Walsh</surname> <given-names>K</given-names></name><name><surname>Ruiz-Lozano</surname> <given-names>P</given-names></name><name><surname>Ranscht</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>T-cadherin is critical for adiponectin-mediated cardioprotection in mice</article-title><source>Journal of Clinical Investigation</source><volume>120</volume><fpage>4342</fpage><lpage>4352</lpage><pub-id pub-id-type="doi">10.1172/JCI43464</pub-id><pub-id pub-id-type="pmid">21041950</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname> <given-names>Y</given-names></name><name><surname>Kaneko</surname> <given-names>M</given-names></name><name><surname>Neyazaki</surname> <given-names>M</given-names></name><name><surname>Nogi</surname> <given-names>T</given-names></name><name><surname>Kato</surname> <given-names>Y</given-names></name><name><surname>Takagi</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin</article-title><source>Protein Expression and Purification</source><volume>95</volume><fpage>240</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2014.01.009</pub-id><pub-id pub-id-type="pmid">24480187</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujishima</surname> <given-names>Y</given-names></name><name><surname>Maeda</surname> <given-names>N</given-names></name><name><surname>Matsuda</surname> <given-names>K</given-names></name><name><surname>Masuda</surname> <given-names>S</given-names></name><name><surname>Mori</surname> <given-names>T</given-names></name><name><surname>Fukuda</surname> <given-names>S</given-names></name><name><surname>Sekimoto</surname> <given-names>R</given-names></name><name><surname>Yamaoka</surname> <given-names>M</given-names></name><name><surname>Obata</surname> <given-names>Y</given-names></name><name><surname>Kita</surname> <given-names>S</given-names></name><name><surname>Nishizawa</surname> <given-names>H</given-names></name><name><surname>Funahashi</surname> <given-names>T</given-names></name><name><surname>Ranscht</surname> <given-names>B</given-names></name><name><surname>Shimomura</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Adiponectin association with T-cadherin protects against neointima proliferation and atherosclerosis</article-title><source>The FASEB Journal</source><volume>31</volume><fpage>1571</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1096/fj.201601064R</pub-id><pub-id pub-id-type="pmid">28062540</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname> <given-names>S</given-names></name><name><surname>Kita</surname> <given-names>S</given-names></name><name><surname>Obata</surname> <given-names>Y</given-names></name><name><surname>Fujishima</surname> <given-names>Y</given-names></name><name><surname>Nagao</surname> <given-names>H</given-names></name><name><surname>Masuda</surname> <given-names>S</given-names></name><name><surname>Tanaka</surname> <given-names>Y</given-names></name><name><surname>Nishizawa</surname> <given-names>H</given-names></name><name><surname>Funahashi</surname> <given-names>T</given-names></name><name><surname>Takagi</surname> <given-names>J</given-names></name><name><surname>Maeda</surname> <given-names>N</given-names></name><name><surname>Shimomura</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The unique prodomain of T-cadherin plays a key role in adiponectin binding with the essential extracellular cadherin repeats 1 and 2</article-title><source>Journal of Biological Chemistry</source><volume>292</volume><fpage>7840</fpage><lpage>7849</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.780734</pub-id><pub-id pub-id-type="pmid">28325833</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardai</surname> <given-names>SJ</given-names></name><name><surname>McPhillips</surname> <given-names>KA</given-names></name><name><surname>Frasch</surname> <given-names>SC</given-names></name><name><surname>Janssen</surname> <given-names>WJ</given-names></name><name><surname>Starefeldt</surname> <given-names>A</given-names></name><name><surname>Murphy-Ullrich</surname> <given-names>JE</given-names></name><name><surname>Bratton</surname> <given-names>DL</given-names></name><name><surname>Oldenborg</surname> <given-names>PA</given-names></name><name><surname>Michalak</surname> <given-names>M</given-names></name><name><surname>Henson</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte</article-title><source>Cell</source><volume>123</volume><fpage>321</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.08.032</pub-id><pub-id pub-id-type="pmid">16239148</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>E</given-names></name><name><surname>Liang</surname> <given-names>P</given-names></name><name><surname>Spiegelman</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>AdipoQ is a novel adipose-specific gene dysregulated in obesity</article-title><source>Journal of Biological Chemistry</source><volume>271</volume><fpage>10697</fpage><lpage>10703</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.18.10697</pub-id><pub-id pub-id-type="pmid">8631877</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hug</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Ahmad</surname> <given-names>NS</given-names></name><name><surname>Bogan</surname> <given-names>JS</given-names></name><name><surname>Tsao</surname> <given-names>TS</given-names></name><name><surname>Lodish</surname> <given-names>HF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin</article-title><source>PNAS</source><volume>101</volume><fpage>10308</fpage><lpage>10313</lpage><pub-id pub-id-type="doi">10.1073/pnas.0403382101</pub-id><pub-id pub-id-type="pmid">15210937</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulpiau</surname> <given-names>P</given-names></name><name><surname>van Roy</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Molecular evolution of the cadherin superfamily</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>41</volume><fpage>349</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2008.09.027</pub-id><pub-id pub-id-type="pmid">18848899</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kita</surname> <given-names>S</given-names></name><name><surname>Maeda</surname> <given-names>N</given-names></name><name><surname>Shimomura</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome</article-title><source>Journal of Clinical Investigation</source><volume>129</volume><fpage>4041</fpage><lpage>4049</lpage><pub-id pub-id-type="doi">10.1172/JCI129193</pub-id><pub-id pub-id-type="pmid">31483293</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitamoto</surname> <given-names>A</given-names></name><name><surname>Kitamoto</surname> <given-names>T</given-names></name><name><surname>Nakamura</surname> <given-names>T</given-names></name><name><surname>Matsuo</surname> <given-names>T</given-names></name><name><surname>Nakata</surname> <given-names>Y</given-names></name><name><surname>Hyogo</surname> <given-names>H</given-names></name><name><surname>Ochi</surname> <given-names>H</given-names></name><name><surname>Kamohara</surname> <given-names>S</given-names></name><name><surname>Miyatake</surname> <given-names>N</given-names></name><name><surname>Kotani</surname> <given-names>K</given-names></name><name><surname>Mineo</surname> <given-names>I</given-names></name><name><surname>Wada</surname> <given-names>J</given-names></name><name><surname>Ogawa</surname> <given-names>Y</given-names></name><name><surname>Yoneda</surname> <given-names>M</given-names></name><name><surname>Nakajima</surname> <given-names>A</given-names></name><name><surname>Funahashi</surname> <given-names>T</given-names></name><name><surname>Miyazaki</surname> <given-names>S</given-names></name><name><surname>Tokunaga</surname> <given-names>K</given-names></name><name><surname>Masuzaki</surname> <given-names>H</given-names></name><name><surname>Ueno</surname> <given-names>T</given-names></name><name><surname>Chayama</surname> <given-names>K</given-names></name><name><surname>Hamaguchi</surname> <given-names>K</given-names></name><name><surname>Yamada</surname> <given-names>K</given-names></name><name><surname>Hanafusa</surname> <given-names>T</given-names></name><name><surname>Oikawa</surname> <given-names>S</given-names></name><name><surname>Sakata</surname> <given-names>T</given-names></name><name><surname>Tanaka</surname> <given-names>K</given-names></name><name><surname>Matsuzawa</surname> <given-names>Y</given-names></name><name><surname>Hotta</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CDH13 polymorphisms are associated with adiponectin levels and metabolic syndrome traits independently of visceral fat mass</article-title><source>Journal of Atherosclerosis and Thrombosis</source><volume>23</volume><fpage>309</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.5551/jat.31567</pub-id><pub-id pub-id-type="pmid">26423718</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname> <given-names>K</given-names></name><name><surname>Okubo</surname> <given-names>K</given-names></name><name><surname>Shimomura</surname> <given-names>I</given-names></name><name><surname>Funahashi</surname> <given-names>T</given-names></name><name><surname>Matsuzawa</surname> <given-names>Y</given-names></name><name><surname>Matsubara</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1)</article-title><source>Biochemical and Biophysical Research Communications</source><volume>221</volume><fpage>286</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1996.0587</pub-id><pub-id pub-id-type="pmid">8619847</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname> <given-names>K</given-names></name><name><surname>Fujishima</surname> <given-names>Y</given-names></name><name><surname>Maeda</surname> <given-names>N</given-names></name><name><surname>Mori</surname> <given-names>T</given-names></name><name><surname>Hirata</surname> <given-names>A</given-names></name><name><surname>Sekimoto</surname> <given-names>R</given-names></name><name><surname>Tsushima</surname> <given-names>Y</given-names></name><name><surname>Masuda</surname> <given-names>S</given-names></name><name><surname>Yamaoka</surname> <given-names>M</given-names></name><name><surname>Inoue</surname> <given-names>K</given-names></name><name><surname>Nishizawa</surname> <given-names>H</given-names></name><name><surname>Kita</surname> <given-names>S</given-names></name><name><surname>Ranscht</surname> <given-names>B</given-names></name><name><surname>Funahashi</surname> <given-names>T</given-names></name><name><surname>Shimomura</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Positive feedback regulation between adiponectin and T-cadherin impacts adiponectin levels in tissue and plasma of male mice</article-title><source>Endocrinology</source><volume>156</volume><fpage>934</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1210/en.2014-1618</pub-id><pub-id pub-id-type="pmid">25514086</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendlov</surname> <given-names>F</given-names></name><name><surname>Conconi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Calreticulin: a multifaceted protein</article-title><source>Nature Education</source><volume>4</volume><elocation-id>1</elocation-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalak</surname> <given-names>M</given-names></name><name><surname>Groenendyk</surname> <given-names>J</given-names></name><name><surname>Szabo</surname> <given-names>E</given-names></name><name><surname>Gold</surname> <given-names>LI</given-names></name><name><surname>Opas</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum</article-title><source>Biochemical Journal</source><volume>417</volume><fpage>651</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1042/BJ20081847</pub-id><pub-id pub-id-type="pmid">19133842</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morisaki</surname> <given-names>H</given-names></name><name><surname>Yamanaka</surname> <given-names>I</given-names></name><name><surname>Iwai</surname> <given-names>N</given-names></name><name><surname>Miyamoto</surname> <given-names>Y</given-names></name><name><surname>Kokubo</surname> <given-names>Y</given-names></name><name><surname>Okamura</surname> <given-names>T</given-names></name><name><surname>Okayama</surname> <given-names>A</given-names></name><name><surname>Morisaki</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title><italic>CDH13</italic> gene coding T-cadherin influences variations in plasma adiponectin levels in the japanese population</article-title><source>Human Mutation</source><volume>33</volume><fpage>402</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1002/humu.21652</pub-id><pub-id pub-id-type="pmid">22065538</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname> <given-names>Y</given-names></name><name><surname>Tobe</surname> <given-names>T</given-names></name><name><surname>Choi-Miura</surname> <given-names>NH</given-names></name><name><surname>Mazda</surname> <given-names>T</given-names></name><name><surname>Tomita</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma</article-title><source>Journal of Biochemistry</source><volume>120</volume><fpage>803</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a021483</pub-id><pub-id pub-id-type="pmid">8947845</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obata</surname> <given-names>Y</given-names></name><name><surname>Kita</surname> <given-names>S</given-names></name><name><surname>Koyama</surname> <given-names>Y</given-names></name><name><surname>Fukuda</surname> <given-names>S</given-names></name><name><surname>Takeda</surname> <given-names>H</given-names></name><name><surname>Takahashi</surname> <given-names>M</given-names></name><name><surname>Fujishima</surname> <given-names>Y</given-names></name><name><surname>Nagao</surname> <given-names>H</given-names></name><name><surname>Masuda</surname> <given-names>S</given-names></name><name><surname>Tanaka</surname> <given-names>Y</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Nishizawa</surname> <given-names>H</given-names></name><name><surname>Funahashi</surname> <given-names>T</given-names></name><name><surname>Ranscht</surname> <given-names>B</given-names></name><name><surname>Izumi</surname> <given-names>Y</given-names></name><name><surname>Bamba</surname> <given-names>T</given-names></name><name><surname>Fukusaki</surname> <given-names>E</given-names></name><name><surname>Hanayama</surname> <given-names>R</given-names></name><name><surname>Shimada</surname> <given-names>S</given-names></name><name><surname>Maeda</surname> <given-names>N</given-names></name><name><surname>Shimomura</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Adiponectin/T-cadherin system enhances exosome biogenesis and decreases cellular ceramides by exosomal release</article-title><source>JCI Insight</source><volume>3</volume><pub-id pub-id-type="doi">10.1172/jci.insight.99680</pub-id><pub-id pub-id-type="pmid">29669945</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker-Duffen</surname> <given-names>JL</given-names></name><name><surname>Nakamura</surname> <given-names>K</given-names></name><name><surname>Silver</surname> <given-names>M</given-names></name><name><surname>Kikuchi</surname> <given-names>R</given-names></name><name><surname>Tigges</surname> <given-names>U</given-names></name><name><surname>Yoshida</surname> <given-names>S</given-names></name><name><surname>Denzel</surname> <given-names>MS</given-names></name><name><surname>Ranscht</surname> <given-names>B</given-names></name><name><surname>Walsh</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>T-cadherin is essential for adiponectin-mediated revascularization</article-title><source>Journal of Biological Chemistry</source><volume>288</volume><fpage>24886</fpage><lpage>24897</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.454835</pub-id><pub-id pub-id-type="pmid">23824191</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherer</surname> <given-names>PE</given-names></name><name><surname>Williams</surname> <given-names>S</given-names></name><name><surname>Fogliano</surname> <given-names>M</given-names></name><name><surname>Baldini</surname> <given-names>G</given-names></name><name><surname>Lodish</surname> <given-names>HF</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A novel serum protein similar to C1q, produced exclusively in adipocytes</article-title><source>Journal of Biological Chemistry</source><volume>270</volume><fpage>26746</fpage><lpage>26749</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.45.26746</pub-id><pub-id pub-id-type="pmid">7592907</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straub</surname> <given-names>LG</given-names></name><name><surname>Scherer</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metabolic messengers: adiponectin</article-title><source>Nature Metabolism</source><volume>1</volume><fpage>334</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/s42255-019-0041-z</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname> <given-names>S</given-names></name><name><surname>Wilson-Kubalek</surname> <given-names>EM</given-names></name><name><surname>Wert</surname> <given-names>D</given-names></name><name><surname>Tsao</surname> <given-names>TS</given-names></name><name><surname>Lee</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The oligomeric structure of high molecular weight adiponectin</article-title><source>FEBS Letters</source><volume>581</volume><fpage>809</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2007.01.046</pub-id><pub-id pub-id-type="pmid">17292892</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemura</surname> <given-names>Y</given-names></name><name><surname>Ouchi</surname> <given-names>N</given-names></name><name><surname>Shibata</surname> <given-names>R</given-names></name><name><surname>Aprahamian</surname> <given-names>T</given-names></name><name><surname>Kirber</surname> <given-names>MT</given-names></name><name><surname>Summer</surname> <given-names>RS</given-names></name><name><surname>Kihara</surname> <given-names>S</given-names></name><name><surname>Walsh</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies</article-title><source>Journal of Clinical Investigation</source><volume>117</volume><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1172/JCI29709</pub-id><pub-id pub-id-type="pmid">17256056</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname> <given-names>Y</given-names></name><name><surname>Kita</surname> <given-names>S</given-names></name><name><surname>Nishizawa</surname> <given-names>H</given-names></name><name><surname>Fukuda</surname> <given-names>S</given-names></name><name><surname>Fujishima</surname> <given-names>Y</given-names></name><name><surname>Obata</surname> <given-names>Y</given-names></name><name><surname>Nagao</surname> <given-names>H</given-names></name><name><surname>Masuda</surname> <given-names>S</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Shimizu</surname> <given-names>Y</given-names></name><name><surname>Mineo</surname> <given-names>R</given-names></name><name><surname>Natsukawa</surname> <given-names>T</given-names></name><name><surname>Funahashi</surname> <given-names>T</given-names></name><name><surname>Ranscht</surname> <given-names>B</given-names></name><name><surname>Fukada</surname> <given-names>SI</given-names></name><name><surname>Maeda</surname> <given-names>N</given-names></name><name><surname>Shimomura</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Adiponectin promotes muscle regeneration through binding to T-cadherin</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-37115-3</pub-id><pub-id pub-id-type="pmid">30626897</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanford</surname> <given-names>C</given-names></name><name><surname>Reynolds</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Characterization of membrane proteins in detergent solutions</article-title><source>Biochimica Et Biophysica Acta (BBA) - Reviews on Biomembranes</source><volume>457</volume><fpage>133</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/0304-4157(76)90009-5</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>YT</given-names></name><name><surname>Hu</surname> <given-names>T</given-names></name><name><surname>Arterburn</surname> <given-names>M</given-names></name><name><surname>Boyle</surname> <given-names>B</given-names></name><name><surname>Bright</surname> <given-names>JM</given-names></name><name><surname>Emtage</surname> <given-names>PC</given-names></name><name><surname>Funk</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>PAQR proteins: a novel membrane receptor family defined by an ancient 7-transmembrane pass motif</article-title><source>Journal of Molecular Evolution</source><volume>61</volume><fpage>372</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1007/s00239-004-0375-2</pub-id><pub-id pub-id-type="pmid">16044242</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Niel</surname> <given-names>G</given-names></name><name><surname>D'Angelo</surname> <given-names>G</given-names></name><name><surname>Raposo</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Shedding light on the cell biology of extracellular vesicles</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>19</volume><fpage>213</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.125</pub-id><pub-id pub-id-type="pmid">29339798</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname> <given-names>T</given-names></name><name><surname>Kamon</surname> <given-names>J</given-names></name><name><surname>Ito</surname> <given-names>Y</given-names></name><name><surname>Tsuchida</surname> <given-names>A</given-names></name><name><surname>Yokomizo</surname> <given-names>T</given-names></name><name><surname>Kita</surname> <given-names>S</given-names></name><name><surname>Sugiyama</surname> <given-names>T</given-names></name><name><surname>Miyagishi</surname> <given-names>M</given-names></name><name><surname>Hara</surname> <given-names>K</given-names></name><name><surname>Tsunoda</surname> <given-names>M</given-names></name><name><surname>Murakami</surname> <given-names>K</given-names></name><name><surname>Ohteki</surname> <given-names>T</given-names></name><name><surname>Uchida</surname> <given-names>S</given-names></name><name><surname>Takekawa</surname> <given-names>S</given-names></name><name><surname>Waki</surname> <given-names>H</given-names></name><name><surname>Tsuno</surname> <given-names>NH</given-names></name><name><surname>Shibata</surname> <given-names>Y</given-names></name><name><surname>Terauchi</surname> <given-names>Y</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Tobe</surname> <given-names>K</given-names></name><name><surname>Koyasu</surname> <given-names>S</given-names></name><name><surname>Taira</surname> <given-names>K</given-names></name><name><surname>Kitamura</surname> <given-names>T</given-names></name><name><surname>Shimizu</surname> <given-names>T</given-names></name><name><surname>Nagai</surname> <given-names>R</given-names></name><name><surname>Kadowaki</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cloning of adiponectin receptors that mediate antidiabetic metabolic effects</article-title><source>Nature</source><volume>423</volume><fpage>762</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1038/nature01705</pub-id><pub-id pub-id-type="pmid">12802337</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname> <given-names>T</given-names></name><name><surname>Nio</surname> <given-names>Y</given-names></name><name><surname>Maki</surname> <given-names>T</given-names></name><name><surname>Kobayashi</surname> <given-names>M</given-names></name><name><surname>Takazawa</surname> <given-names>T</given-names></name><name><surname>Iwabu</surname> <given-names>M</given-names></name><name><surname>Okada-Iwabu</surname> <given-names>M</given-names></name><name><surname>Kawamoto</surname> <given-names>S</given-names></name><name><surname>Kubota</surname> <given-names>N</given-names></name><name><surname>Kubota</surname> <given-names>T</given-names></name><name><surname>Ito</surname> <given-names>Y</given-names></name><name><surname>Kamon</surname> <given-names>J</given-names></name><name><surname>Tsuchida</surname> <given-names>A</given-names></name><name><surname>Kumagai</surname> <given-names>K</given-names></name><name><surname>Kozono</surname> <given-names>H</given-names></name><name><surname>Hada</surname> <given-names>Y</given-names></name><name><surname>Ogata</surname> <given-names>H</given-names></name><name><surname>Tokuyama</surname> <given-names>K</given-names></name><name><surname>Tsunoda</surname> <given-names>M</given-names></name><name><surname>Ide</surname> <given-names>T</given-names></name><name><surname>Murakami</surname> <given-names>K</given-names></name><name><surname>Awazawa</surname> <given-names>M</given-names></name><name><surname>Takamoto</surname> <given-names>I</given-names></name><name><surname>Froguel</surname> <given-names>P</given-names></name><name><surname>Hara</surname> <given-names>K</given-names></name><name><surname>Tobe</surname> <given-names>K</given-names></name><name><surname>Nagai</surname> <given-names>R</given-names></name><name><surname>Ueki</surname> <given-names>K</given-names></name><name><surname>Kadowaki</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions</article-title><source>Nature Medicine</source><volume>13</volume><fpage>332</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nm1557</pub-id><pub-id pub-id-type="pmid">17268472</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname> <given-names>T</given-names></name><name><surname>Iwabu</surname> <given-names>M</given-names></name><name><surname>Okada-Iwabu</surname> <given-names>M</given-names></name><name><surname>Kadowaki</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Adiponectin receptors: a review of their structure, function and how they work</article-title><source>Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism</source><volume>28</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2013.09.003</pub-id><pub-id pub-id-type="pmid">24417942</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.48675.011</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>James</surname><given-names>David E</given-names></name><role>Reviewing Editor</role><aff><institution>The University of Sydney</institution><country>Australia</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Birnbaum</surname><given-names>Morris</given-names> </name><role>Reviewer</role><aff><institution>University of Pennsylvania</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>[Editors’ note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.]</p><p>Thank you for submitting your work entitled &quot;Native adiponectin existing in serum binds with T-cadherin, but not with AdipoRs nor Calreticulin&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Morris Birnbaum (Reviewer #3).</p><p>Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in <italic>eLife</italic>.</p><p>This study focused on elucidating the physiological binding partner(s) for native adiponectin. With cell culture based studies, they have revealed that serum adiponectin exclusively bound to T-cadherin, but not to the &quot;classical&quot; AdipoR receptors nor Calreticulin. The strength of the study is that they have shown binding of &quot;native&quot; adiponectin to T-cadherin as this has not been shown before. However, the study has several weaknesses which preclude publication in <italic>eLife</italic>. First, the binding system used is somewhat &quot;dirty&quot; limiting careful biochemical analyses. Second, the overall advance of the study is unclear as it has already been shown that adiponectin binds to T-cadherin. Third, all reviewers highlighted weaknesses with the binding assay pinpointing the inability of the authors to reach saturation binding, an essential criterion for a receptor-ligand interaction. Finally, as highlighted by reviewer 1, much more work is required to prove a lack of interaction between adiponectin and the other receptor systems.</p><p><italic>Reviewer #1:</italic></p><p>This manuscript presents data showing serum adiponectin binds to T-cadherin overexpressed in HEK293 cells as well as endogenous T-cadherin in C2C12 cells. These findings are solid and convincing since in such experiments adiponectin is in native forms and being adsorbed directly in such forms. The claim that T-cadherin is a &quot;receptor&quot; for adiponectin is justified by these data and conforms to other solid papers in the field. These data do not add much to the literature as it is already established that adiponectin binds to T-cadherin, although this is a new way of demonstrating the phenomenon. But the claim is convincing.</p><p>On the other hand, the failure to show binding of serum adiponectin to other purported receptor molecules (R1 and R2 as well as Calreticulin) is more difficult to interpret. The claim that these are not true receptors could be true, but it is impossible to prove a negative. What if there are &quot;accessory&quot; proteins required to confer binding activity to these other putative receptors? Expression of the receptors alone would not be sufficient to display binding in that case. Normally, ligand-receptor interactions are quantified by binding of pure ligand with pure receptor, which allows binding constants to be calculated. This is not the case here, since the ligand is in a complex mixture (serum) and the &quot;receptor&quot; is also within a complex structure (cell membrane). These complications raise concerns about the conclusion, and have caused other groups to use gene KO mice to interrogate putative &quot;receptor&quot; function.</p><p>On balance, this paper should be published since it raises an important question for the field. Publication would also highlight the need to determine binding affinities for the putative receptors. However, the study doesn't add mechanistic information to the field, and doesn't define why dysfunction of adiponectin occurs when the R1/R2 receptors are deleted in mice. For those reasons, it could be argued that this paper belongs in a specialty journal.</p><p>One other point is that careful editing of this manuscript for proper English usage would be mandatory prior to publication.</p><p><italic>Reviewer #2:</italic></p><p>In this study, Kita et al. have focused on the elucidation of physiological binding partner(s) for native adiponectin. With cell culture based studies, they have revealed that serum adiponectin exclusively bound to T-cadherin, but not to AdipoR nor Calreticulin. While this study contains potential interests, several issues need to be properly addressed to enhance the significance of this study.</p><p>1) Due to molecular structure of T-cadherin protein, it remains elusive to guess the mode(s) of action for adiponectin signaling. More discussion and/or speculation would be more helpful for general readers to understand adiponectin action and signaling.</p><p>2) Along the same line, it is unclear whether T-cadherin might behave as a typical receptor protein for adiponectin. For example, typical receptors are saturated by ligands. However, provided data (Figures 1, 2 and 3) did not show any saturation pattern nor dose response. This issue needs to be properly addressed by experimental data.</p><p>3) The authors demonstrated that native adiponectin bound to T-cadherin. Have you compared the binding affinity with native and recombinant adiponectin proteins to three potential receptors? If there is any difference, it needs to be described and discussed.</p><p><italic>Reviewer #3:</italic></p><p>In spite of the identification of adiponectin quite a number of years ago, the nature of its receptors remains controversial. The rationale for the current study is that the major criterion for evaluating a potential receptor should be that it binds native adiponectin and not just recombinant product. This seems quite reasonable and therefore the strength of the paper is that it seeks to accomplish that. The weakness is that the nature of the protocol involves performing the binding study on a very complex, on might say &quot;dirty&quot; system, in which it is challenging to infer the actual biochemical even being measured. At a minimum, the authors' need to be much more precise in their language and judicious in what they claim the data show. For example, the authors state &quot;These results clearly indicate that T-cadherin can bind native adiponectin.&quot; This is a gross overinterpretation of this experiment. What the authors show is that overexpression of T-cadherin in cells allows them to bind increased amounts of adiponectin. There is no information to indicated that the adiponectin is binding directly to T-cadherin or, for that matter, that T-cadherin is involved in the binding of hormone. This interpretation might be plausible, but it is far from proven.</p><p>The authors do demonstrate that the binding is concentration dependent, which is important for true receptor binding, but they do not establish saturability, which is essential to arguing the physiological relevance of the event being measured. Thus, it would add to the weight of the argument of they could show a full binding curve up to the point of saturability. It is relatively straightforward to vary expression to make sure the receptor level is low enough that it can be saturated with the adiponectin levels present in serum.</p><p>[Editors’ note: what now follows is the decision letter after the authors submitted for further consideration.]</p><p>Congratulations, we are pleased to inform you that your article, &quot;Native adiponectin in serum binds to cells expressing T-cadherin, but not AdipoRs or calreticulin&quot;, has been accepted for publication in <italic>eLife</italic> as a Short Report article.</p><p>While the reviewers still identified some shortcomings with your study, it was generally considered that your paper makes an important contribution to the field. In particular, there is an abundance of evidence in the literature to show that adiponectin signals via the ADIPOR1 and 2 receptors. Your work questions the breadth of this conclusion and shows that as a minimum the field needs to carefully consider the role of this alternate adiponectin receptor, T cadherin. This paper clearly shows that adiponectin binds to T-cadherin with considerable affinity under somewhat physiological conditions. As to whether the origin or nature of the ligand influences the binding specificity is unclear but this is certainly something important to consider that this work highlights. While, as pointed out by two of the reviewers, there is a long way to go to ascertain how the adiponectin-T-cadherin interaction signals in cells this is perhaps something for a future study.</p><p>Please address as best you can each of the points raised by the reviewers as noted below. Also I noted that some restructuring of your figures is necessary to consolidate space and to improve the presentation of the data. Furthermore, I still believe you could shorten the article without loss of clarity.</p><p><italic>Reviewer #1:</italic></p><p>This paper provides data supporting the view that binding of adiponectin to cells is through T-cadherin rather than other purported receptor types. There are three issues that diminish the impact of the paper:</p><p>1) The first paragraph is an overly long &quot;stream of consciousness&quot; type of Introduction that should be heavily edited and organized into multiple paragraphs around the several discrete ideas.</p><p>2) The major impact of this study would be that bio-effects of adiponectin are mediated through T-cadherin, not the other putative receptors, but unfortunately no bio-effects are studied in these experiments. While the results are very interesting and certainly provocative, a definitive experiment on this key point showing that T-cadherin but not the other receptors mediates important bio-effects is missing.</p><p>3) The cell biology/microscopy data are too limited. Multiple fields should be shown and appropriate controls with null signal. The data should be quantified from many fields as well.</p><p><italic>Reviewer #2:</italic></p><p>In this work, Kita et al. have demonstrated that native adiponectin would exclusively bind to T-cadherin. With cell culture model, they showed that serum or purified adiponectin preferentially bound to T-cadherin but not to AdipoR nor Calreticulin. Although they provided more data and tried to strengthen Discussion part in the resubmitted manuscript, it still has technical limitations to reach the firm conclusion.</p><p>1) Although it has been reported that adiponectin binds to AdipoRs, calreticulin, and T-cadherin, they argued that the major binding protein for native adiponectin is T-cadherin. If the binding affinity of native adiponectin to adipoRs or calreticulin would be much weaker than T-cadherin, it seems that the experimental condition in this study might be too harsh to detect weak interaction with others. They have to adopt alternative methods to affirm the extent of protein interactions. Along the same line, they need to measure/compare binding affinity of recombinant adiponectin with other proteins including AdipoR and Calreticulin.</p><p>2) To convince that native adiponectin exclusively binds to T-cadherin, it is crucial to provide positive control data.</p><p>3) It has been suggested to examine intracellular signaling cascades such as phospho-AMPK and phospho-p38 upon the interaction between native adiponectin and potential receptors.</p><p><italic>Reviewer #3:</italic></p><p>I was ambivalent about this manuscript the first time around and the authors have only improved it with the additional experiments. In all honesty, this will never be the cleanest study and will not have the highest level of impact due to lack of mechanism, whatever the authors do to address the issues. However, I continue to believe that it brings up a valid point about the ambiguity of the true adiponectin receptor and the data are strong enough to provide a valid challenge to the dogma. On balance, I recommend acceptance.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.48675.012</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>[Editors’ note: the author responses to the first round of peer review follow.]</p><disp-quote content-type="editor-comment"><p>This study focused on elucidating the physiological binding partner(s) for native adiponectin. With cell culture based studies, they have revealed that serum adiponectin exclusively bound to T-cadherin, but not to the &quot;classical&quot; AdipoR receptors nor Calreticulin. The strength of the study is that they have shown binding of &quot;native&quot; adiponectin to T-cadherin as this has not been shown before.</p><p>However, the study has several weaknesses which preclude publication in eLife. First, the binding system used is somewhat &quot;dirty&quot; limiting careful biochemical analyses.</p></disp-quote><p>We used HMW adiponectin purified from serum (Fukuda et al., 2017, PMID: 28325833) and full-length recombinant adiponectin produced by HEK293 cells in our revised manuscript, and they gave essentially the same results. Furthermore, we would like to emphasize that the ligand in serum is the most natural ligand that maintains its ability to interact with the physiological binding partner. Numerous constituents, including a large number of proteins, exert adequate blocking effects to investigate whether the interaction between the physiological ligand and binding protein is specific. Moreover, the use of a recombinant ligand may make the experiment unreproducible because the same recombinant ligand cannot be made at another site. The ligand-receptor interaction in a more purified system can have mean if the ligand can bind with the receptor in a more physiological situation like in serum as our experiment. The results of our new experiment indicate that recombinant adiponectin has a limited affinity to T-cadherin due to the presence of less of the HMW form.</p><p>The results obtained were shown in Figure 1B and 1D. We added the following sentences.</p><p>Results and Discussion</p><p>“We directly examined mouse serum as the ligand solution, including the most native adiponectin, purified adiponectin from mouse serum (Fukuda et al., 2017), and full-length recombinant adiponectin produced in HEK293 cells. […] Recombinant adiponectin contained a lower amount of HMW multimer adiponectin than mouse serum and purified adiponectin from serum (Figure 1B).</p><p>Results and Discussion</p><p>“The treatment of cells with different preparations of adiponectin at 4°C for 1 hr resulted in the binding of prepared adiponectin only to cells expressing mouse T-cadherin (Figure 1D). Mouse serum and purified adiponectin showed similar binding, whereas recombinant adiponectin containing a lower amount of 6-mer and the HMW multimer exhibited markedly weaker binding (Figure 1D).”</p><disp-quote content-type="editor-comment"><p>Second, the overall advance of the study is unclear as it has already been shown that adiponectin binds to T-cadherin.</p></disp-quote><p>The binding of HMW recombinant adiponectin to T-cadherin was initially discovered in 2004 (Hug C et al., 2004); however, it has not been investigated in detail because it lacks an intracellular domain. We previously reported a molecular interaction between serum derived purified HMW adiponectin and Fc-fusion purified T-cadherin with high affinity (KD=1.0 nM) (Fukuda et al., 2017). Moreover, we demonstrated that T-cadherin mediated the exosome-stimulating function of adiponectin (Obata et al., 2018). However, as discussed in the Abstract, reported receptors for adiponectin have not yet been simultaneously examined on their adiponectin binding under equal conditions. The present study established by WB that native HMW (&gt; 6mer) adiponectin in serum and highly purified serum-derived multimer adiponectin bound to cells expressing T-cadherin, but not to those expressing AdipoRs or calreticulin. An important issue in the present study is that native HMW adiponectin, either in serum or highly purified, did not appear to bind to cells expressing AdipoRs or calreticulin, but did bind to those expressing T-cadherin in the same set of experiments. Based on these results, we speculate that AdipoRs and/or calreticulin may function as adiponectin receptors for LMW forms such as globular adiponectin, possibly on the site of cells after HMW adiponectin binding to cell-surface T-cadherin is cleaved. We discussed this possibility in our response to comment 4 by the Editor.</p><disp-quote content-type="editor-comment"><p>Third, all reviewers highlighted weaknesses with the binding assay pinpointing the inability of the authors to reach saturation binding, an essential criterion for a receptor-ligand interaction.</p></disp-quote><p>We showed the saturable binding of native adiponectin in serum in Figure 1E. The binding isotherm obtained is consistent with the high-affinity interaction we reported previously using purified HMW adiponectin with purified T-cadherin (Fukuda et al., 2017).</p><p>The results obtained were shown in Figure 1E. We added the following sentence.</p><p>Results and Discussion</p><p>“The dose-response study revealed the specific and saturable binding of native adiponectin in serum to cells expressing T-cadherin (Figure 1E).”</p><disp-quote content-type="editor-comment"><p>Finally, as highlighted by reviewer 1, much more work is required to prove a lack of interaction between adiponectin and the other receptor systems.</p></disp-quote><p>We simultaneously compared the candidate receptors. The expression of T-cadherin gave a strong band of bound adiponectin, which is consistent with our previous finding showing that recombinant T-cadherin binds HMW adiponectin in a 1: 1 ratio with high affinity. If the receptor has meaningful affinity, it will bind and give a visible band on WB, similar to that of T-cadherin. However, there was no detectable band on the AdipoR or calreticulin lane. Furthermore, AdipoR was discovered by expression cloning. Therefore, the ectopic introduction of AdipoRs promotes adiponectin binding. The Nature study also showed that HEK293 cells overexpressing AdipoRs bound <italic>E. coli</italic> recombinant globular adiponectin (Supplementary Figure 2A and 2B, Yamauchi et al., 2003). Therefore, difficulties are associated with speculating about the requirement for “accessory” proteins to confer adiponectin binding activity to AdipoRs.</p><p>Numerous studies have indicated that AdipoRs mediate adiponectin signaling. Therefore, there may be additional activating mechanisms of AdipoRs by adiponectin, i.e., reductive or proteolytic generation of the trimer, monomer, and/or globular adiponectin. The present study focused on the direct binding of native HMW adiponectin (more than a hexamer) and the results obtained suggest the activation of AdipoRs by these LMW forms, possibly on the site of cells after HMW adiponectin binding to cell surface T-cadherin is cleaved.</p><p>On the other hand, in the case of calreticulin, this was evidenced by a neutralizing antibody treatment inhibiting the adiponectin interaction with cells (Takemura et al., 2007). Therefore, “accessory” proteins may be required to confer adiponectin binding activity to calreticulin. We also revised our discussion on this point to keep the possibility of calreticulin mediating the adiponectin interaction with cells.</p><p>We added a detailed discussion on this important assumption as follows.</p><p>Results and Discussion</p><p>“Adiponectin is an atypically abundant circulating factor that is exclusively secreted from adipocytes as a trimer, hexamer, and HMW multimer. […] Therefore, some “accessory” proteins may be required to confer adiponectin binding activity to calreticulin.”</p><p>We also revised the Abstract as follows.</p><p>“Adiponectin is an adipocyte-derived atypically abundant circulating factor that protects various organs and tissues through its receptors, AdipoRs, calreticulin, and T-cadherin. […] Collectively, these results suggest that T-cadherin is the major binding partner of native adiponectin in serum.”</p><p>We also revised conclusive sentences at the bottom of the Results and Discussion sections as follows.</p><p>“The present results may further contribute to clarifying the activating mechanism of AdipoRs by LMW adiponectin, generated by reduction or proteolytic cleavage, followed by HMW adiponectin binding to cell surface T-cadherin.”</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>This manuscript presents data showing serum adiponectin binds to T-cadherin overexpressed in HEK293 cells as well as endogenous T-cadherin in C2C12 cells. These findings are solid and convincing since in such experiments adiponectin is in native forms and being adsorbed directly in such forms. The claim that T-cadherin is a &quot;receptor&quot; for adiponectin is justified by these data and conforms to other solid papers in the field. These data do not add much to the literature as it is already established that adiponectin binds to T-cadherin, although this is a new way of demonstrating the phenomenon. But the claim is convincing.</p></disp-quote><p>The binding of HMW recombinant adiponectin to T-cadherin was initially discovered in 2004 (Hug C et al., 2004); however, it has not been investigated in detail because it lacks an intracellular domain. We previously reported a molecular interaction between serum-derived purified HMW adiponectin and Fc-fusion purified T-cadherin with high affinity (KD=1.0 nM) (Fukuda et al., 2017). Moreover, we demonstrated that T-cadherin mediated the exosome-stimulating function of adiponectin (Obata et al., 2018). However, as discussed in the Abstract, reported receptors for adiponectin have not yet been simultaneously examined under equal conditions on their adiponectin binding. The present study established by WB that native HMW (&gt; 6mer) adiponectin in serum and highly purified serum derived multimer adiponectin bound to cells expressing T-cadherin, but not to those expressing AdipoRs or calreticulin. An important issue in the present study is that native HMW adiponectin, either in serum or highly purified, did not appear to bind to cells expressing AdipoRs or calreticulin, but did bind to those expressing T-cadherin in the same set of experiments. Based on these results, we speculate that AdipoRs and/or calreticulin may function as adiponectin receptors for LMW forms such as globular adiponectin, possibly on the site of cells after HMW adiponectin binding to cell surface T-cadherin is cleaved. We discussed this possibility in our response to reviewer #1’s comment 3.</p><disp-quote content-type="editor-comment"><p>On the other hand, the failure to show binding of serum adiponectin to other purported receptor molecules (R1 and R2 as well as Calreticulin) is more difficult to interpret. The claim that these are not true receptors could be true, but it is impossible to prove a negative. What if there are &quot;accessory&quot; proteins required to confer binding activity to these other putative receptors? Expression of the receptors alone would not be sufficient to display binding in that case. Normally, ligand-receptor interactions are quantified by binding of pure ligand with pure receptor, which allows binding constants to be calculated. This is not the case here, since the ligand is in a complex mixture (serum) and the &quot;receptor&quot; is also within a complex structure (cell membrane). These complications raise concerns about the conclusion, and have caused other groups to use gene KO mice to interrogate putative &quot;receptor&quot; function.</p></disp-quote><p>We appreciate the valuable comment. In the revised manuscript, we compared the binding of native adiponectin in serum, purified native adiponectin, and recombinant full-length adiponectin produced in HEK293 cells. The results obtained indicated that only cells expressing T-cadherin and not the other receptors bound these preparations of adiponectin. However, recombinant adiponectin with a lower amount of HMW multimer adiponectin showed weak binding at a physiological concentration (20 µg/mL) of adiponectin. The results obtained were shown in Figure 1B and 1D. We added the following sentences.</p><p>Results and Discussion</p><p>“We directly examined mouse serum as the ligand solution, including the most native adiponectin, purified adiponectin from mouse serum (Fukuda et al., 2017), and full-length recombinant adiponectin produced in HEK293 cells. […] Recombinant adiponectin contained a lower amount of HMW multimer adiponectin than mouse serum and purified adiponectin from serum (Figure 1B).”</p><p>Results and Discussion</p><p>“The treatment of cells with different preparations of adiponectin at 4°C for 1 hr resulted in the binding of prepared adiponectin only to cells expressing mouse T-cadherin (Figure 1D). Mouse serum and purified adiponectin showed similar binding, whereas recombinant adiponectin containing a lower amount of 6-mer and the HMW multimer exhibited markedly weaker binding (Figure 1D).”</p><p>Furthermore, we would like to emphasize that the ligand in serum is the most natural ligand that maintains its ability to interact with the physiological binding partner. Numerous constituents, including a large number of proteins, exert adequate blocking effects to investigate whether the interaction between the physiological ligand and binding protein is specific. Moreover, the use of a recombinant ligand may make the experiment unreproducible because the same recombinant ligand cannot be made at another site. The ligand-receptor interaction in a more purified system can have mean if the ligand can bind with the receptor in a more physiological situation like in serum as our experiment The results of our new experiment indicate that recombinant adiponectin has a limited affinity to T-cadherin due to the presence of less of the HMW form.</p><p>The expression of T-cadherin gave a strong band of bound adiponectin, which is consistent with our previous finding showing that recombinant T-cadherin binds HMW adiponectin in a 1: 1 ratio with high affinity. If the receptor has meaningful affinity, it will bind and give a visible band on WB, similar to that of T-cadherin. However, there was no detectable band on the AdipoR or calreticulin lane. Furthermore, AdipoR was discovered by expression cloning. Therefore, the ectopic introduction of AdipoRs promotes adiponectin binding. The Nature study also showed that HEK293 cells overexpressing AdipoRs bound <italic>E. coli</italic> recombinant globular adiponectin (Supplementary Figure 2A and 2B, Yamauchi et al., 2003). Therefore, difficulties are associated with speculating about the requirement for “accessory” proteins to confer adiponectin binding activity to AdipoRs.</p><p>On the other hand, in the case of calreticulin, this was evidenced by a neutralizing antibody treatment inhibiting the adiponectin interaction with cells (Takemura Y et al., 2007). Therefore, “accessory” proteins may be required to confer adiponectin binding activity to calreticulin. We also revised our discussion on this point to keep the possibility of calreticulin mediating the adiponectin interaction with cells.</p><p>We added a detailed discussion on this important assumption as follows.</p><p>Results and Discussion</p><p>“We simultaneously compared three adiponectin receptors. The expression of T-cadherin gave a strong band of bound adiponectin, which is consistent with our previous finding showing that recombinant Tcadherin binds HMW adiponectin in a 1: 1 ratio with high affinity (Fukuda et al., 2017). […] Therefore, difficulties are associated with speculating about the requirement for some “accessory” proteins to confer adiponectin binding activity to AdipoRs.”</p><p>Results and Discussion</p><p>“On the other hand, in the case of calreticulin, this was evidenced by a neutralizing antibody treatment inhibiting the adiponectin interaction with cells (Takemura et al., 2007). Therefore, some “accessory” proteins may be required to confer adiponectin binding activity to calreticulin.”</p><disp-quote content-type="editor-comment"><p>On balance, this paper should be published since it raises an important question for the field. Publication would also highlight the need to determine binding affinities for the putative receptors. However, the study doesn't add mechanistic information to the field, and doesn't define why dysfunction of adiponectin occurs when the R1/R2 receptors are deleted in mice. For those reasons, it could be argued that this paper belongs in a specialty journal.</p></disp-quote><p>We appreciate the valuable comment. Numerous studies indicated that AdipoRs mediate adiponectin signaling. Therefore, there may be additional activating mechanisms of AdipoRs by adiponectin, i.e., reductive or proteolytic generation of the trimer, monomer, and/or globular adiponectin. The present study focused on the direct binding of native HMW adiponectin (more than hexamer) and the results obtained suggest the activation of AdipoRs by these LMW forms, possibly on the site of cells after HMW adiponectin binding to cell-surface T-cadherin is cleaved. We added a detailed discussion on this important assumption as follows.</p><p>Results and Discussion</p><p>“Since numerous studies indicated that AdipoRs mediate adiponectin signaling in a number of cell types, an additional activating mechanism for AdipoRs by adiponectin, i.e., the reductive or proteolytic generation of the trimer, monomer, and/or globular adiponectin, may exist. The results of the present study, which focused on the direct binding of native HMW adiponectin, may indicate the activation of AdipoRs by low-molecular-weight (LMW) forms.”</p><p>We also revised the Abstract as follows.</p><p>“Adiponectin is an adipocyte-derived atypically abundant circulating factor that protects various organs and tissues through its receptors, AdipoRs, calreticulin, and T-cadherin. […] Collectively, these results suggest that T-cadherin is the major binding partner of native adiponectin in serum.”</p><p>We also revised conclusive sentences at the bottom of the Results and Discussion sections as follows.</p><p>“The present results may further contribute to clarifying the activating mechanism of AdipoRs by LMW adiponectin, generated by reduction or proteolytic cleavage, followed by HMW adiponectin binding to cell surface T-cadherin.”</p><disp-quote content-type="editor-comment"><p>One other point is that careful editing of this manuscript for proper English usage would be mandatory prior to publication.</p></disp-quote><p>The revised manuscript was proofread by a native speaker of English.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>In this study, Kita et al. have focused on the elucidation of physiological binding partner(s) for native adiponectin. With cell culture based studies, they have revealed that serum adiponectin exclusively bound to T-cadherin, but not to AdipoR nor Calreticulin. While this study contains potential interests, several issues need to be properly addressed to enhance the significance of this study.</p><p>1) Due to molecular structure of T-cadherin protein, it remains elusive to guess the mode(s) of action for adiponectin signaling. More discussion and/or speculation would be more helpful for general readers to understand adiponectin action and signaling.</p></disp-quote><p>We appreciate the valuable comment. We added a detailed discussion on the mode of action of adiponectin through T-cadherin as below.</p><p>Results and Discussion</p><p>“T-cadherin binds clinically important HMW multimer adiponectin with high affinity (Fukuda et al., 2017) and mediates adiponectin-induced exosome biogenesis and ceramide efflux to exosomes (Obata et al., 2018). […] These findings support Tcadherin mediating adiponectin functions as a receptor for native HMW multimer adiponectin (Kita et al., 2019).”</p><disp-quote content-type="editor-comment"><p>2) Along the same line, it is unclear whether T-cadherin might behave as a typical receptor protein for adiponectin. For example, typical receptors are saturated by ligands. However, provided data (Figures 1, 2 and 3) did not show any saturation pattern nor dose response. This issue needs to be properly addressed by experimental data.</p></disp-quote><p>We appreciate the valuable comment. We demonstrated the saturable binding of native adiponectin in serum. The binding isotherm obtained is consistent with the high-affinity interaction we reported previously using purified HMW adiponectin with purified T-cadherin (Fukuda et al., 2017). The results obtained were shown in Figure 1D. The following sentences were added.</p><p>Results and Discussion</p><p>“The dose-response study revealed the specific and saturable binding of native adiponectin in serum to cells expressing T-cadherin (Figure 1E).”</p><disp-quote content-type="editor-comment"><p>3) The authors demonstrated that native adiponectin bound to T-cadherin. Have you compared the binding affinity with native and recombinant adiponectin proteins to three potential receptors? If there is any difference, it needs to be described and discussed.</p></disp-quote><p>We appreciate the valuable comment. In the revised manuscript, we compared the binding of native adiponectin in serum, purified native adiponectin, and recombinant full-length adiponectin produced in HEK293 cells. The results obtained indicated that only cells expressing T-cadherin and not the other receptors bound these preparations of adiponectin. However, recombinant adiponectin with a lower amount of HMW multimer adiponectin showed weak binding at a physiological concentration (20 μg/mL) of adiponectin.</p><p>The results obtained were shown in Figure 1B and 1D. The following sentences were added.</p><p>Results and Discussion</p><p>“We directly examined mouse serum as the ligand solution, including the most native adiponectin, purified adiponectin from mouse serum (Fukuda et al., 2017), and full-length recombinant adiponectin produced in HEK293 cells. […] Recombinant adiponectin contained a lower amount of HMW multimer adiponectin than mouse serum and purified adiponectin from serum (Figure 1B).”</p><p>Results and Discussion</p><p>“The treatment of cells with different preparations of adiponectin at 4°C for 1 hr resulted in the binding of prepared adiponectin only to cells expressing mouse T-cadherin (Figure 1D). Mouse serum and purified adiponectin showed similar binding, whereas recombinant adiponectin containing a lower amount of 6-mer and the HMW multimer exhibited markedly weaker binding (Figure 1D).”</p><p>Once again, we are sincerely grateful to reviewer #2 for the constructive suggestions, which have improved the quality of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>In spite of the identification of adiponectin quite a number of years ago, the nature of its receptors remains controversial. The rationale for the current study is that the major criterion for evaluating a potential receptor should be that it binds native adiponectin and not just recombinant product. This seems quite reasonable and therefore the strength of the paper is that it seeks to accomplish that. The weakness is that the nature of the protocol involves performing the binding study on a very complex, on might say &quot;dirty&quot; system, in which it is challenging to infer the actual biochemical even being measured.</p></disp-quote><p>We appreciate the valuable comment. We compared the binding of native adiponectin in serum, purified native adiponectin, and recombinant full-length adiponectin produced in HEK293 cells. The results obtained indicated that only cells expressing T-cadherin and not the other receptors bound these preparations of adiponectin. However, recombinant adiponectin with lower amounts of HMW multimer adiponectin showed weak binding at a physiological concentration (20 μg/mL) of adiponectin. These results were shown in Figure 1B and 1D. We added the following sentences.</p><p>Results and Discussion</p><p>“We directly examined mouse serum as the ligand solution, including the most native adiponectin, purified adiponectin from mouse serum (Fukuda et al., 2017), and full-length recombinant adiponectin produced in HEK293 cells. […] Recombinant adiponectin contained a lower amount of HMW multimer adiponectin than mouse serum and purified adiponectin from serum (Figure 1B).”</p><p>Results and Discussion</p><p>“The treatment of cells with different preparations of adiponectin at 4°C for 1 hr resulted in the binding of prepared adiponectin only to cells expressing mouse T-cadherin (Figure 1D). Mouse serum and purified adiponectin showed similar binding, whereas recombinant adiponectin containing a lower amount of 6-mer and the HMW multimer exhibited markedly weaker binding (Figure 1D).”</p><p>Furthermore, we would like to emphasize that the ligand in serum is the most natural ligand that maintains its ability to interact with the physiological binding partner. Numerous constituents, including a large number of proteins, exert adequate blocking effects to investigate whether the interaction between the physiological ligand and binding protein is specific. Moreover, the use of a recombinant ligand may make the experiment unreproducible because the same recombinant ligand cannot be made at another site. The ligand-receptor interaction in a more purified system can have mean if the ligand can bind with the receptor in a more physiological situation like in serum as our experiment The results of our new experiment indicate that recombinant adiponectin has limited affinity to T-cadherin due to the presence of less of the HMW form.</p><disp-quote content-type="editor-comment"><p>At a minimum, the authors' need to be much more precise in their language and judicious in what they claim the data show. For example, the authors state &quot;These results clearly indicate that T-cadherin can bind native adiponectin.&quot; This is a gross overinterpretation of this experiment. What the authors show is that overexpression of T-cadherin in cells allows them to bind increased amounts of adiponectin. There is no information to indicated that the adiponectin is binding directly to T-cadherin or, for that matter, that T-cadherin is involved in the binding of hormone. This interpretation might be plausible, but it is far from proven.</p></disp-quote><p>We appreciate the valuable comment. The revised manuscript was proofread by a native English speaker.</p><p>Since we previously reported a serum-derived purified APN interaction with purified Fc-fusion Tcadherin (JBC, 2017), the statement “These results clearly indicate that T-cadherin can bind native adiponectin”was replaced as follows.</p><p>Results and Discussion</p><p>“We previously reported that purified recombinant T-cadherin bound purified adiponectin with an affinity of KD=1.0 nM (Fukuda et al., 2017). The present results showed the saturable binding of native adiponectin in serum to cells expressing T-cadherin, which is consistent with previous findings (Fukuda et al., 2017).”</p><disp-quote content-type="editor-comment"><p>The authors do demonstrate that the binding is concentration dependent, which is important for true receptor binding, but they do not establish saturability, which is essential to arguing the physiological relevance of the event being measured. Thus, it would add to the weight of the argument of they could show a full binding curve up to the point of saturability. It is relatively straightforward to vary expression to make sure the receptor level is low enough that it can be saturated with the adiponectin levels present in serum.</p></disp-quote><p>We appreciate the valuable comment. We demonstrated the saturable binding of native adiponectin in serum. The binding isotherm obtained is consistent with the high-affinity interaction we reported previously using purified HMW adiponectin with purified T-cadherin (Fukuda et al., 2017). The results obtained were shown in Figure 1E. The following sentences were added.</p><p>Results and Discussion</p><p>“The dose-response study revealed the specific and saturable binding of native adiponectin in serum to cells expressing T-cadherin (Figure 1E).”</p><p>[Editors’ note: the author responses to the re-review follow.]</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>This paper provides data supporting the view that binding of adiponectin to cells is through T-cadherin rather than other purported receptor types. There are three issues that diminish the impact of the paper:</p><p>1) The first paragraph is an overly long &quot;stream of consciousness&quot; type of Introduction that should be heavily edited and organized into multiple paragraphs around the several discrete ideas.</p></disp-quote><p>We reorganized Introduction section according to your kind advice as follows.</p><p>“Adiponectin is a circulating factor that is secreted from adipocytes (Hu et al., 1996; Maeda et al., 1996; Nakano et al., 1996; Scherer et al., 1995). […] We herein demonstrated that native adiponectin in serum bound to cells expressing T-cadherin, but not to those expressing AdipoRs or calreticulin.”</p><disp-quote content-type="editor-comment"><p>2) The major impact of this study would be that bio-effects of adiponectin are mediated through T-cadherin, not the other putative receptors, but unfortunately no bio-effects are studied in these experiments. While the results are very interesting and certainly provocative, a definitive experiment on this key point showing that T-cadherin but not the other receptors mediates important bio-effects is missing.</p></disp-quote><p>Thank you for pointing the most important point to be addressed. It is well known that adiponectin stimulates intracellular signaling cascades such as phospho-AMPK and phospho-p38. And the loss of AdipoRs was shown to decrease these signaling. One explanation will be the generation of low molecular weight form of adiponectin such as globular form after binding to T-cadherin. However, it was recently reported that the primary cellular function of AdipoR1 and AdipoR2 is to maintain membrane fluidity (Ruiz M et al., J Lipid Res. 2019 May;60(5):995-1004). Loss of them might disturb membrane fluidity and thereby decrease signaling. Another explanation may be intracellular signaling by HMW-adiponectin internalization through binding to T-cadherin without interaction with AdipoRs. In future studies, we will carefully examine whether HMW-adiponectin stimulates such signaling or not and whether endocytosis of adiponectin through T-cadherin is required or not.</p><disp-quote content-type="editor-comment"><p>3) The cell biology/microscopy data are too limited. Multiple fields should be shown and appropriate controls with null signal. The data should be quantified from many fields as well.</p></disp-quote><p>We appreciate the valuable comment. The fluorescent microscopy data (Figure 2H) only indicate that the tagged receptors are correctly expressed, together with Western blotting data (Figure 2E). At this moment, it seems kind of reasonable to us that quantification by microscopy data may not be required because we have more accurate quantified data by Western blots.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>In this work, Kita et al. have demonstrated that native adiponectin would exclusively bind to T-cadherin. With cell culture model, they showed that serum or purified adiponectin preferentially bound to T-cadherin but not to AdipoR nor Calreticulin. Although they provided more data and tried to strengthen Discussion part in the resubmitted manuscript, it still has technical limitations to reach the firm conclusion.</p><p>1) Although it has been reported that adiponectin binds to AdipoRs, calreticulin, and T-cadherin, they argued that the major binding protein for native adiponectin is T-cadherin. If the binding affinity of native adiponectin to adipoRs or calreticulin would be much weaker than T-cadherin, it seems that the experimental condition in this study might be too harsh to detect weak interaction with others. They have to adopt alternative methods to affirm the extent of protein interactions. Along the same line, they need to measure/compare binding affinity of recombinant adiponectin with other proteins including AdipoR and Calreticulin.</p></disp-quote><p>Thank you for pointing an important discussion point in this study. As discussed in the Results and Discussion section (ninth paragraph), in the case of calreticulin, the interaction with adiponectin was evidenced by a neutralizing antibody treatment inhibiting the adiponectin interaction with cells expressing calreticulin (Takemura et al., 2007). So, possibilities of the requirement of calreticulin for adiponectin binding such as the requirement of some accessory protein may exist. In the case of AdipoRs, AdipoR was discovered by expression cloning, as discussed in the Results and Discussion section (eighth paragraph). Expression cloning requires repeated washing steps before separation by FACS. Therefore, the overexpression of AdipoR is expected to promote firm ligand binding. The initial discovery of AdipoRs also indicated that HEK293 cells overexpressing AdipoRs bound <italic>E. coli</italic> recombinant globular adiponectin (Yamauchi et al., 2003). Therefore, difficulties are associated with speculating about the much weaker binding affinity or requirement for some “accessory” proteins to confer adiponectin binding activity to AdipoRs. Rather, HMW-adiponectin may not bind to AdipoRs, but the globular form may do.</p><disp-quote content-type="editor-comment"><p>2) To convince that native adiponectin exclusively binds to T-cadherin, it is crucial to provide positive control data.</p></disp-quote><p>We appreciate the valuable comment. We previously reported and established HMW-adiponectin binding to T-cadherin in several ways including Biacore analysis and loss of tissue accumulation of adiponectin in T-cadherin KO mice (Fukuda et al., 2017, Matsuda et al., 2015). Therefore in this sense, T-cadherin can be thought of as positive control. Based on nearly the same amounts of receptors expressed on the cell surface as judged by PA-tag expression outside of the cells, native adiponectin bound to the cells expressing T-cadherin but not to the cells expressing AdipoR1.</p><disp-quote content-type="editor-comment"><p>3) It has been suggested to examine intracellular signaling cascades such as phospho-AMPK and phospho-p38 upon the interaction between native adiponectin and potential receptors.</p></disp-quote><p>Thank you for pointing the most important point to be addressed. It has been shown that adiponectin stimulates intracellular signaling cascades such as phospho-AMPK and phospho-p38. And the loss of AdipoRs decreases these signaling. One explanation will be the generation of low molecular weight form of adiponectin such as globular form after binding to T-cadherin. However, it was recently reported that the primary cellular function of AdipoR1 and AdipoR2 is to maintain membrane fluidity (Ruiz M et al., J Lipid Res. 2019 May;60(5):995-1004). Loss of them might disturb membrane fluidity and thereby decrease signaling. Another explanation may be intracellular signaling by HMW-adiponectin internalization through binding to T-cadherin without interaction with AdipoRs. In our future studies, we will carefully examine whether HMW-adiponectin stimulates such signaling or not and whether endocytosis of adiponectin through T-cadherin is required or not.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>I was ambivalent about this manuscript the first time around and the authors have only improved it with the additional experiments. In all honesty, this will never be the cleanest study and will not have the highest level of impact due to lack of mechanism, whatever the authors do to address the issues. However, I continue to believe that it brings up a valid point about the ambiguity of the true adiponectin receptor and the data are strong enough to provide a valid challenge to the dogma. On balance, I recommend acceptance.</p></disp-quote><p>Thank you very much for evaluating the significance of our study. Regarding the mechanism, how adiponectin input intracellular signaling, it must be the next important study. It is well known that adiponectin stimulates intracellular signaling cascades such as phospho-AMPK and phospho-p38. And the loss of AdipoRs decreases these signaling. One explanation will be the generation of low molecular weight form of adiponectin such as globular form after binding to T-cadherin. However, it was recently reported that the primary cellular function of AdipoR1 and AdipoR2 is to maintain membrane fluidity (Ruiz M et al., J Lipid Res. 2019 May;60(5):995-1004). Loss of them might disturb membrane fluidity and thereby decrease signaling. Another explanation may be intracellular signaling by HMW-adiponectin internalization through binding to T-cadherin without interaction with AdipoRs. In our future studies, we will carefully examine whether HMW-adiponectin stimulates such signaling or not and whether endocytosis of adiponectin through T-cadherin is required or not.</p></body></sub-article></article>